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ABSTRACT 
As Africa faces the challenges of its renewal or renaissance, the HIV/AIDS epidemic poses 
the greatest potential barrier to the attainment of this vision (Makgoba, 2001 in Dorrington, 
Bourne, Bradshaw, Laubscher & Timaeus, 2001). The development of an HIV vaccine that is 
safe, effective and affordable, has been widely contemplated as a necessary supplement to 
already established interventions. In preparation for HTV vaccine trials in South Africa the 
current project aimed to assess students' understanding (knowledge and perceptions) and 
experiences of vaccination in general, and to explore if these were associated with 
demographics such as motherhood and gender. A parallel aim was to assess students' 
knowledge and expectations of HIV vaccination and trial participation. A sample of 33 
students was recruited from university residences at the University of Natal, 
Pietermaritzburg. Participants were interviewed via a semi-structured interview schedule. The 
data collected was then coded and analysed using content analysis, while Chi - square 
analysis was used to evaluate if demographics such as gender and motherhood were 
systematically associated with various responses. 
The results revealed that the vast majority of participants (97%) knew the purpose of 
vaccination, stating that it was to promote health and prevent illness. Most participants (67%) 
knew that vaccination works by mobilising the immune system (vaccination mechanism). 
The vast majority of participants (91%) could name at least one vaccine preventable disease. 
Uptake of childhood immunisation was reportedly high (88%) while adult uptake of 
immunisation was low (33%). A significant minority (36%) reported that they had 
experienced side effects but understood these to be an integral part of vaccination. Thirty 
percent of participants stated they were willing to participate (WTP) in a hypothetical vaccine 
trial, 33 % of participants were not WTP and 15% were not sure. Motivations for trial 
participation were reportedly influenced most by personal incentives of altruism (39%) and 
barriers such as perceived significant physical risk (61%). In general, knowledge and 
experiences of vaccination were not associated with gender or with motherhood. The results 
suggest that more awareness of HIV vaccine trials is needed. In this regard education should 
emphasise that the prospective vaccine will be preventive, that only healthy people can 
volunteer and that the HIV vaccine will not guarantee immunity to HIV infection. 
Suggestions are made for future research into motivations, barriers and incentives to facilitate 
an ethical process of vaccine trial participation. 
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Chapter 1: GENERAL OVERVIEW 
1.1 Introduction 
Current UNAIDS statistics on HIV morbidity and mortality rates are increasing, indicating 
that the HIV/AIDS pandemic is worse than the Black Death of the 14th century, the bubonic 
plague epidemic that killed over SO million people throughout Asia and Europe (Makgoba, 
Solomon, Johan & Tucker, 2002). As South Africa embraces its relatively new democracy, 
after a long but victorious fight against an oppressive regime under apartheid rule, AIDS 
threatens the exciting prospects of life as a 'rainbow nation'. At the turn of the twentieth 
century the AIDS pandemic remains an unprecedented challenge for both health prevention 
and medical research, with approximately 42 million people living with AIDS world-wide 
(UNAIDS - WHO, 2002). Of this figure South Africa has the largest number of people living 
with HTV man any other country (Bekker & Morris, 2002; Dorrington et al., 2001). Like with 
many developing countries the severity of the AIDS pandemic in South Africa has expressed 
itself in human, public health, social and economic terms. While various strategies to control 
the epidemic have been implemented, behavioural interventions have been the most widely 
used prevention strategy against the AIDS crisis. Antiretroviral therapy1 and drugs for infants 
to reduce mother to child transmission and ameliorate symptoms for HIV/AIDS sufferers 
have also been recognised treatments for HIV infection. However, these are not widely 
available in South Africa. Up until now, collective intervention efforts have not made a 
significant health impact (Harrison, Smit & Myer, 2000). Thus, an HIV preventive vaccine2 
has been widely and seriously considered as a necessary supplementary intervention to 
control the spread of HTV infection. 
In general, immunisation3 remains one of the most cost effective and efficacious health 
interventions to prevent disease, saving an estimated 3 million lives each year throughout the 
world (Hall & O'Brien, 1998). Efforts by the Expanded Programme on Immunisation (EPI) 
1 Antiretroviral - a group of drugs, which reduce the reproduction of HIV in the body (Barrett, 1998). 
2 Vaccine - "Vaccines are materials derived from infectious agents which are administered in order to stimulate 
the immune system to produce an effective immune response similar to that produced by the corresponding 
infectious agent but without its associated disease" (Schoub, 2002, p. 561). 
Immunisation - another synonym for vaccination like inoculation, often used in the context of childhood 
preventive health measures and also refers to the process or behaviour of being immunised. 
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have focussed on universal childhood immunisation from disease including polio, measles, 
and hepatitis (Henderson, 2000; Wright, 1995). As the third decade of the AIDS pandemic 
unfolds, there remains no HIV vaccine that has been demonstrated to be safe and effective. It 
has been widely emphasised that 
" ...the successful development of effective HIV preventive vaccines is likely to 
require that many candidate vaccines be studied simultaneously in different 
populations around the world. This in turn will require a large international co-
operative effort drawing on partners from various health sectors, intergovernmental 
organisations, government, research institutions, industry, and affected populations" 
(UNAIDS, 2000, p. 5). 
Although developing countries bear the brunt of the AIDS burden (International AIDS 
Vaccine Initiative [LAVI], 1998; Joint United Nations Program on AIDS in collaboration with 
the World Health Organisation [UNAIDS-WHO], 2002), thus far only two HIV vaccine trial 
initiatives have been carried out in Africa (Weidle, Mastro, Grant, Nkengasong & Macharia, 
2002) of an approximate 30 HIV vaccine trials currently being run world-wide (Slack et al., 
2000). Therefore it is imperative that HIV initiatives also increase in this region. During the 
process of HIV vaccine development and implementation, attention to ethical standards will 
be required to avoid exploitation of vulnerable communities - most prevalent in developing 
countries. Thus, the partners involved in the development of an HTV vaccine will have to 
address the difficult ethical concerns that arise (Makgoba, et al., 2002). 
In many respects, South Africa is one ideal place in sub-Saharan Africa to conduct HTV 
vaccine trials, in that it meets the necessary criteria (Abdool Karim, 2002), and has been 
identified as such by the World Health organisation (WHO) (Barrett, 1998). Initiatives such 
as the South African AIDS Vaccine Initiative (SAAVI) can therefore play a key role in 
facilitating the development of a local vaccine and in ensuring that the rights of potential 
participants are protected. Communities in the developing world have sometimes been 
considered good candidates for medical research because they tend to be poor, malnourished, 
illiterate and desperate (Moodley, 2002). "HIV in South Africa flourishes most in areas that 
are burdened by unemployment, homelessness, welfare dependency, prostitution, crime, a 
high school drop-out rate, and social unrest" (Lindegger & Wood, 1995, p. 8). The 
safeguarding of rights of these often vulnerable communities is therefore crucial (UNAIDS, 
2000). Certain South African communities, especially those in rural areas, may also be 
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described as vulnerable due to the high poverty rates accompanied by a myriad of social ills 
including a high incidence of HIV infection. Therefore these communities must be protected 
from potential exploitation in research (Moodley, 2002). This is particularly poignant in 
South Africa where undermining fundamental human rights (through apartheid) was 
legitimised. 
In South Africa, the relevance of psychology to the community has been questioned in the 
past, especially given its 'apparent silence' in the apartheid era (Lindegger & Wood, 1995). 
Psychology as a profession has been accused of marginalizing itself from the majority in 
South Africa, with psychological services being seen generally as a luxury and accessible to 
the wealthier minority (Heyns, 1992 in Lindegger & Wood, 1995). The AIDS pandemic in 
South Africa marks another historical era, posing a major challenge to the health care 
industry. As a behavioural science, psychology has an especially important role to play with 
various aspects of AIDS and its prevention (ibid). Specifically, psychologists may intervene 
through policy development; preventive education campaigns; education and training of lay 
counsellors; psychological counselling for screening (and for) HIV-affected people, their 
families, co-workers and carers; psychological services for the 'worried well'; assisting with 
training of health care workers; and conducting AIDS related research (Schneider, 1989 in 
Lindegger & Wood, 1995). Therefore psychology has a role to play in the preparation and 
implementation of trial phases for HTV trials (Abdool Karim, 2002), which are due to begin 
in 2003 in South Africa. In conjunction with a series of vaccination studies being carried out 
in the country (da Silva, 2003; Lindegger, Quayle & Slack, 2003) the current study aims to 
explore knowledge, perceptions of and experiences with vaccination. These results may be 
used to inform education campaigns and informed consent procedures (which are required for 
adequate preparation) for communities in preparation for vaccine trials. 
1.2 Rationale for the study 
The development of local HTV vaccines has been identified as an urgent need in South Africa 
(Abdool Karim, 2002; Bekker & Morris, 2002; Galloway, 2000; Williamson C, Morris, 
Rybicki & Williamson, A.L., 2000). As South Africa is in the process of commencing safety 
trials, the following study, in conjunction with a series of studies currently underway in South 
Africa, has a role to play in the general preparation of HIV vaccine trials. According to Slack 
etal. 
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"Vaccine trials may be alien or unwelcome concepts in communities from which 
participants for trials are drawn. A counter-view posits that, since other forms of 
immunisation and vaccination are already so widespread, HIV vaccine trials may be 
perceived as extensions of familiar health protective practices" (2000, p. 291). 
The current study assumes the latter view. Therefore it is based on the premise that South 
Africans have a longstanding history with infant immunisation, childhood immunisation, 
adult vaccination and vaccination for travel purposes, as forms of preventive health practices. 
Therefore community attitudes to vaccination could be surveyed in preparation for HIV 
vaccine trials (Slack et al., 2000). 
Various studies have also been carried out throughout the globe assessing people's 
knowledge, attitudes and experiences toward vaccination in general and these have yielded 
variable results. Studies on people's willingness to participate in hypothetical HIV vaccine 
trials have also been documented together with perceived barriers to participation. The 
findings are presented in Chapter 2. In South Africa however, information on people's 
knowledge, experiences and attitudes toward general vaccination is sparse, with only a few 
studies having been documented. Even fewer studies have investigated perceptions of 
potential HIV vaccination in South Africa. Moreover, given the advent of HIV vaccine trials 
more studies of this nature are especially required now. 
In general, vaccine development is highly technical and complex. It is important to uncover 
peoples' knowledge, attitudes and experiences with vaccination in general to identify 
important health beliefs in different communities so as to aid researchers in the conduct of 
culturally sensitive research. Misconceptions and attitudes toward vaccination could also be 
extracted. This would help to generate ways of communicating the complex technicalities of 
vaccines in a more meaningful and acceptable way for the communities concerned. This is 
one way that communities may impact on implementation of vaccine development 
(UNAIDS, 2000). Therefore the current study in conjunction with two other studies being 
conducted at the University of Natal, Pietermaritzburg (da Silva, 2003; Lindegger et al., 
2003) attempt to bridge a knowledge gap by exploring indigenous knowledge, experiences 
and attitudes toward vaccination in general with different samples of the South African 
population. A practical application of these findings would be to inform education campaigns 
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and informed consent procedures as part of the preparation for HTV vaccine trials in South 
Africa. 
1.3 Aims and objectives of the study 
The current study is an investigation of university students' understandings of vaccination, 
and their experiences. The key objectives are to assess students': 
> Understandings of vaccination: Knowledge and perceptions of vaccination in general, 
including perceived barriers to vaccination; 
> Experiences of vaccination generally; 
> Knowledge of and expectations toward HIV vaccination and participation in a 
hypothetical HIV vaccine trial; and 
> To explore if particular knowledge and experiences are associated with demographics 
such as motherhood and gender. 
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Chapter 2: LITERATURE REVIEW 
Chapter 2: Part 1: The AIDS pandemic and the urgency of an HIV vaccine 
2.1 Introduction 
The following chapter is made up of three parts, prefaced by an introductory definitions 
section. Part one contextualises the AIDS crisis and highlights the urgency of HIV vaccine 
development. With the advent of HIV vaccine trials, part two begins by outlining the 
importance of protecting the rights of participants of future vaccine trials and concludes with 
a discussion on the necessary preparation for an HIV vaccine trial. Finally, part three presents 
empirical studies reviewing knowledge, attitudes and experiences toward general 
vaccinations. The implications for future HIV vaccine trials are also presented. 
2.2 Definition of terms 
The term understanding refers to the process of grasping meaning (or fact) of a given subject, 
which is either present or implied (Pearsall, 1998). Knowledge can be broadly defined as the 
possession of explicit information pertaining to a given subject (Rooney, 1999). Perception 
refers to the process through which we give meaning to information we get from our senses 
(Louw & Edwards, 1998). Wade and Tavris (1996, p. 663) define an attitude as a "fairly 
stable opinion toward a person, object, or activity, containing a cognitive element 
(perceptions and beliefs) and an emotional element (positive or negative feelings)". 
Experience refers to the condition of having undergone or been affected by a particular event 
(Ayto, 1991). 
2.3 Context 
2.3.1 The ADDS epidemic 
Variable stages of the epidemic are being encountered globally. Some countries are 
experiencing the early stages accompanied by economic and social changes, resulting in the 
explosive spread of HIV. In other countries, like Uganda, the rates of infection have been 
significantly reduced (Masemola & Gray, 2002). According to UNAIDS - WHO (2002) 
statistics an estimated total of 5 million infections and 3 million AIDS related deaths occurred 
in 2002. Sub-Saharan African has been described as the AIDS epicentre of the world, with an 
approximated 48% of all new infections (Morris, Williamson, Gray & Tiemessen, 2000). 
Growth rates of new HIV infections have also been reported from Asia and the Pacific - with 
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7.2 million people living with AIDS in that region. Eastern Europe and Central Asian 
republics, especially Baltic states, have also been reported areas of growth rates (UNAIDS -
WHO, 2002). Other growth regions include the Russian federation and several central Asian 
republics, and India, where almost 4 million people live with HIV/AIDS. In South Africa five 
million adults and children are currently living with AIDS (ibid) but the worst affected group 
appears to be women aged 20-30 years, with the highest incidence of new infections being 
amongst women between 15-30 years (Harrison et al., 2000). 
As the third decade of the AIDS epidemic is approached, its impact is dramatic, leaving 
behind human, public health, social and economic ramifications, and in extreme situations the 
epidemic is driving some nations towards destitution (UNAIDS - WHO, 2002). In several 
African countries, the economic impact alone could amount to a loss of more than 10% of 
potential economic production (IAVI, 1998). In South Africa concern is mounting about the 
potential costs to companies, as a large sector of the working force has only just begun to be 
affected by HIV/AIDS-related morbidity and mortality rates (Rosen, Simon, Thea & Vincent, 
2000). Thus, the AIDS pandemic requires that decisive action be taken to slow down its 
progression. 
2.3.2 Interventions against the AIDS pandemic 
Although extensive research has been conducted in die field of HTV/AIDS mere remains no 
proven preventive vaccine or cure. In the following section interventions that have been the 
main focus of HIV prevention and treatment will be presented. 
2.3.2.1 Drug therapies for AIDS 
To date HIV/AIDS control efforts have focused mainly on prevention, while lagging behind 
in providing adequate treatment, care and support to people living with HIV/AIDS (Harries, 
2002). Less than 4 % of people in need of antiretroviral treatment receive the drugs and fewer 
than 10 % of people with HIV/AIDS have access to palliative care or treatment for 
opportunistic infections (UNAIDS -WHO, 2002). The package of care for already infected 
people includes: screening for sexually transmitted infections, psycho-social support, clinical 
care for opportunistic infections (e.g. tuberculosis), palliative care for terminal illness, home 
based care, care and support for orphans, prevention of mother to child transmission of HIV, 
and possible antiretroviral drugs (Harries, 2002). In general, antiretroviral medication has 
been demonstrated to be the most effective treatment for slowing HIV-related disease 
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(UNAIDS, 2000) and has led to a major reduction of mortality rates in developed countries 
(Barrett, 1998). Although this has meant that AIDS has become a chrome disease in 
developed countries, like diabetes or hypertension, it is not the case with South Africa and 
other developing countries (Barrett, 1998, IAVI, 1998). 
Antiretroviral drugs are not available to the majority of South Africans affected by 
HIV/AIDS for various reasons (C. Williamson, Morris, Rybicki & A.L. Williamson, 2000). 
In many countries competing national priorities constrain allocation of resources to 
HIV/AIDS care, support and treatment, especially in sub-Saharan Africa and Asia (UNAIDS 
- WHO, 2002). This is certainly the case in South Africa where poverty and economic 
disparities are also rife. Antiretroviral therapies are costly, complicated to administer, require 
close medical monitoring and can lead to significant adverse effects (UNAIDS, 2000). 
Furthermore, there remain several challenges to effective therapy and these include: the 
development of resistance to treatment, drug toxicity, the failure of therapy to eradicate the 
latent viral reservoir in the body and insufficient adherence to treatment regimens by patients 
(van Rensburg, 2002). Wood (2002) proposes that the development of an effective 
therapeutic vaccine could form complementary or alternative treatment for HIV/AIDS. 
Precedents for the use of therapeutic vaccines in other viral diseases after exposure include 
rabies, herpes simplex and hepatitis B (Wood, 2002). 
In South Africa treatment and care of people living with HIV/AIDS has also become highly 
politicised, with availability and delivery of such services dominating media debate regarding 
public health policy. One commonly held view is that South Africa has adequate resources to 
control the HIV/AIDS epidemic, especially given the fact that countries with lower per capita 
income than South Africa, like Uganda, have already had major successes (Abdool Karim, 
2000a). Yet another view, which contradicts popular perceptions, is that the cost of drugs is 
not the only factor involved in bringing effective treatment to AIDS sufferers but also 
requires fully resourced, specialised clinics and close monitoring of patients for blood viral 
load and levels of CD4 cells (among other factors) which will take time for the South African 
public health care service to provide (Lecatsas, 2000). However, most researchers from 
various disciplines do concur that single-course, single drug treatment to prevent mother to 
child transmission should be more readily available in South Africa (Abdool Karim, 2000a; 
Lecatsas, 2000; Soderlund, 1999 in Abdool Karim, 2000a), especially in the light of the 
average 25% seroprevalence rate among pregnant women (Mclntyre & Gray, 2000). 
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2.3.2.2 Behaviour change interventions 
HIV is principally transmitted behaviourally - primarily through 'unprotected' sexual 
intercourse. Thus, efforts to change high-risk behaviours have become a chief focus of HIV 
prevention. Research has indicated that certain behavioural interventions have met with a 
degree of success (Harrison et al., 2000). These include information, education and 
communication programmes, condom promotion and behaviour change initiatives to decrease 
number of sexual partners and delaying the age of sexual initiation and promoting abstinence. 
In South Africa women between ages 15 and 30 years tend to be the most vulnerable to HIV 
infection. This may be attributed to various reasons including poverty, limited access to 
society's resources, and inequalities both within their public and private relations (Barrett, 
1998). Thus, for any potential behavioural strategy to be rendered relevant and effective it 
needs to address these disparities. Increasing women's access to female condoms (Barrett, 
1998) and empowering young women with skills to successfully negotiate condom use 
(Harrison et al., 2000) are some possible ways of how these issues may be addressed. 
There is both empirical evidence and theoretical support for the efficacy of various behaviour 
change interventions in reducing high-risk behaviour and increasing condom use. Several 
empirical studies have found that behaviour interventions increased knowledge of 
HIV/AIDS, improved participants' attitudes, increased both the intention to use and the use 
of condoms, and reduced the number of sexual partners, although these have not had a 
significant impact on the incidence of HIV infection (Harrison et al., 2000). This alludes to 
the fact that knowledge alone does not necessitate change. Nonetheless, common elements in 
interventions that led to positive outcomes have been identified (see table 2.1). In South 
Africa many behavioural programmes have been carried out over the past ten years. Three 
areas of major action include Information, Education and Communication (DEC), peer 
education and behaviour risk reduction (Harrison et al., 2000). D5C programmes are 
particularly relevant early in an epidemic, when focus must be on raising awareness and 
conveying accurate knowledge. In South Africa a high level of awareness exists among the 
general population, with the aid of mass media efforts on television, radio, youth magazines 
(such as Laduma and Lovelife) and billboards and newspaper advertisements. Thus, the 
emphasis of policy makers, researchers and programmers needs to shift toward actions that 
will lead to an increase in preventive behaviours (ibid). 
9 
Theoretical support for the effectiveness of behaviour change interventions is most prominent 
in cognitive behaviour theories. These theories emphasise the individual as a rational 
instigator of change. Thus, the view that knowledge, attitudes, and beliefs determine AIDS 
related practice (the KABP paradigm) is a component of this theory. The KABP paradigm, 
which dominates social scientific AIDS research and prevention programmes, also 
encapsulates the Theory of Reasoned Action (TRA) and the Health Belief Model (HBM) 
(Jaffe, 1996). The assumptions of the KABP paradigm and its proponents have been 
challenged for their emphasis on the individual as a rational actor in altering behaviour (Jaffe, 
1996). Recent theoretical contributions emphasise the importance of group norms and 
collective change (ibid). Thus, while knowledge is a necessary precedent to behaviour 
change it is not sufficient to initiate such a change but rather interventions that impart skills, 
target specific risk groups and take into account the socio-cultural context of community are 
most effective (Harrison et al., 2000). 
Systematic reviews of behaviour interventions with a positive influence show that successful 
interventions have addressed: 
Outcomes: aim for effect on timing and frequency of sexual intercourse, numbers of partners, and use 
of condoms or other contraceptives 
Design: positive association between intervention design and outcomes 
Objectives: include a narrow focus with behavioural goals 
Theoretical basis: based on social learning or other cognitive-behavioural theory 
Content: include basic, accurate information on risk; repeat essential messages 
Normative process: strengthen group norms 
Skill-based focus: include experiential activities, especially the modelling and practice of 
communication and negotiation skills; interpersonal negotiation and communication skills found to 
strengthen behavioural outcomes 
Duration: interventions that increased condom use and involved fewer partners tended to be longer in 
duration; sufficient time for 3-5 intensive sessions needed for skills acquisition and retention 
Community emphasis: focus on community and cultural aspects; design culturally 
appropriate/relevant and language-appropriate interventions; embed AIDS intervention in broader 
contexts; promote integration into community 
Participation: create forums for open discussion; solicit participation involvement 
Table 2.1 Elements of successful behaviour intervention programmes (Adopted from Harrison et al., 
2000, p.285) 
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In sum, AIDS is a humanitarian crisis (Makgoba, et al.s 2002). Various interventions have 
been employed in South Africa. These have been predominately preventive with less 
attention paid to care of already infected people. These efforts have made a modest impact on 
the overall crisis. Therefore these interventions need consolidation and an exhaustive care 
package implemented more vigorously (Harries, 2002). Furthermore, there is dissension in 
political ranks with regards to how and what needs to be done to curb the pandemic. " South 
Africa is experiencing an unprecedented, explosive ADDS epidemic ... To defeat this 
epidemic, however, the greatest challenge is for South Africans to act with common purpose" 
(Abdool Karim, 2000b, p. 262). 
It is a commonly held view among ADDS researchers that an HIV preventive vaccine even 
with low efficacy could have a significant impact on the epidemic. However, these efforts 
would still be rendered insufficient without permanent behaviour change in the population -
despite the best intentions of a prospective vaccine (Schoub, 2002). Therefore, while the need 
for an HIV vaccine is both compelling and urgent (UNAIDS, 2000) it should complement 
current interventions targeting behaviour change. Finally, any meaningful challenge to the 
AIDS epidemic requires increased and concerted support from the international community, 
both for antiretroviral drugs and for basic prevention and care packages (Harries, 2002). 
2.3.3 HIV preventive vaccines for sub-Saharan Africa 
From a number of perspectives it would be advantageous for sub-Saharan Africa to develop 
HIV preventive vaccines. Firstly, an HIV vaccine, in conjunction with existing interventions, 
would help to significantly reduce the high seroconversion rates in sub-Saharan Africa 
(Williamson et al., 2000). Secondly, the high rates of infection typical of the sub-Saharan 
region would enable phase II1 trials to be conducted, which require larger numbers of people 
at high risk in order to test vaccine efficacy (Makgoba et al., 2002). In addition, the heavy 
AIDS burden, and limited access to treatment in this region strongly suggest that countries in 
sub-Saharan Africa would benefit from conducting trials locally (Galloway, 2000). 
Traditionally most HIV vaccine trials have taken place in developed countries, where HIV-1 
subtype B is more prevalent, and therefore vaccine development has been geared towards that 
particular clade4 (Morris, Williamson, Gray & Tiemessen, 2000). However, in many 
4 Clade - also referred to as subtype or strain. 
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developing countries, especially in sub-Saharan Africa, HIV -1 subtype C is more prevalent 
(Galloway, 2000; Morris et al., 2000; UNAIDS - WHO, 2002; Williamson, et al., 2000). 
South Africa is an ideally situated sub-Saharan African country to carry out the task of 
developing candidate vaccines for HIV-1 subtype C (Abdool Karim, 2002; Bekker & Morris, 
2002; Galloway, 2000). At a workshop held in 1998 in South Africa, participants decided 
that sub-Saharan Africa cannot rely solely on vaccine development being conducted 
elsewhere focusing on a different clade but rather that South Africa should take responsibility 
for clade C strain of HIV-1 (Galloway, 2000). HIV-1 subtype C is emerging as the most 
significant virus in the global epidemic, accounting for over 55% of all HIV-infections 
globally (Esparza & Bhamarapravati, 2000). While HIV-1 subtype B has been more prevalent 
in the United States and Europe, subtype C viruses are predominant in high prevalence 
countries in sub-Saharan Africa such as South Africa, Zimbabwe, Zambia, Botswana and 
Malawi (Williamson et al., 2000). The responsibility of South Africa would therefore involve 
the development of a vaccine that addresses country-specific health problems, while 
simultaneously keeping up with progress in other countries and on vaccines developed for 
other clades. South Africa is also well placed to develop and run clinical vaccines trials of 
HIV because it has well-established clinical trial infrastructure and capability (Abdool Karim, 
2002). The South African AIDS Vaccine Initiative (SAAVI), established in 1999 to 
coordinate the pursuit of local HIV/AIDS vaccine, has been working towards clinical safety 
trials that were scheduled to begin in 2002, and were delayed and subsequently scheduled for 
mid-year 2003. 
It is important to note that there is no 'quick fix' solution to the AIDS crisis. Even after an 
effective vaccine is found it may take some time before communities that desperately need it 
access it. It has been previously noted that vaccines have typically reached developing 
countries on average twenty years after being approved in developed nations (Mirken, 2001). 
One example is the Hepatitis B vaccine that was only available in Africa over ten years after 
it was licensed in developed countries (Ijsselmuiden & Faden, 1992). According to a public 
address by the General Secretary of the United Nations (2002), Africa is affected by multiple 
crises including; HIV/AIDS, poverty and in security, and political instability. Thus the 
expedient and efficient development of an HIV vaccine requires a conducive environment 
informed by rigorous science and ethics, and characterised by governmental commitment, 
public and private partnerships, and international collaboration. 
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2.4 Development of global immunisation programmes 
2.4.1 Introduction 
In general vaccination has proven to be one of the most affordable and effective health 
interventions and prevention strategies against disease. The following section presents a short 
review of the history and development of vaccination programmes as they are known today. 
The origins of vaccination can be traced back 200 years ago to the work of Jenner. In 1796 
Jenner successfully used the cowpox virus to protect a person from smallpox disease. Jenner 
succeeded in inducing a 'primed' state by sufficiently infecting the patient thereby 
heightening the response of the immune system to secondary infection leading to prevention 
of disease (Pless, n.d.; Trika, Ma Man Lei, Yani & Juarso, n.d.). Since Jenner numerous 
vaccines have been developed and mass immunisation efforts promulgated through the 
Expanded Programme on Immunisation (EPI). Success of vaccination includes the 
eradicating of polio and smallpox by 1975 and 1977, respectively. In addition, infant 
vaccination has been made mandatory in many countries. 
2.4.2 The Expanded Programme on Immunisation (EPI) 
In 1987 a sector of the World Health Organisation (WHO) targeted the year 2000 for the 
global eradication of poliomyelitis giving leverage to the EPI. For years now the global 
community has been close to achieving universal childhood immunisation against childhood 
diseases. These include tuberculosis, diphtheria, pertussis and tetanus. Through the efforts of 
the EPI highly successful vaccines that have been able to protect from disease include polio, 
measles, and hepatitis (Henderson, 2000; Wright, 1995). 
The EPI developed global immunisation policy, which has been extended by Ministries of 
Health into their respective countries. Among other things, two large strides toward 
eradication of poliomyelitis have made. The first was the establishment of immunisation 
schedules, networks of immunisation clinics that made vaccines accessible, and the 
specification of conditions that represented contraindications to immunisation. The second 
was surveillance of program success with regards to dosage, adverse effects and disease 
reduction attributable to immunisation. Thereafter, a global schedule of immunisation for 
BCG and polio, DTP and polio, and measles was adopted. To date this schedule is still the 
norm though it has been tailored to each country (Wright, 1995). 
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The public health gains due to vaccination are unquestionable. Such efforts have lead to the 
eradication of diseases such as smallpox and polio, and likewise measles, tuberculosis, 
diphtheria, pertussis and tetanus are following suit. Once incurable, life-threatening diseases 
have now been abated through global immunisation efforts. Extensive research in the field of 
vaccine development is currently being conducted in different parts of the world. 
In the same way that a concerted effort and commitment has aided the cause of the EPI, 
individual countries and the various regions will have to act with common purpose if an HIV 
vaccine is to be developed. Nationally this translates into collaboration between different 
stakeholders including government and key decision-makers, researchers, ethicists, and local 
communities. Internationally this implies sharing new knowledge and resources. These 
efforts to develop an HIV vaccine will not by themselves alleviate the crisis but should 
supplement ongoing strategies, e.g. behavioural interventions. 
2.5 HIV vaccine development and clinical trials of HIV vaccines 
2.5.1. The development of HIV vaccines 
Since the initial discovery of HIV in the 1980's there have been significant scientific and 
social challenges. While it may be argued that decisive action to moderate the epidemic has 
on the whole been slow it may be also be said that stated motivation to do so has not wavered 
(IAVI, 1998). 
Conventional vaccines may be categorised as either live attenuated vaccines, which are a 
weakened forms of the original virus, or killed inactivated vaccines (see Table 2.2). Both 
types have been demonstrated to be safe, provide sterilising immunity and have led to the 
eradication of disease such as smallpox (van Rensburg, 2002). In the case of HIV/AIDS 
however, both options are not practical or plausible. Vaccines can be further categorised by 
their outcomes into preventive or therapeutic vaccines, both of which have specific functions 
and strategies. Vaccination can be universal or target particular individuals, and can control, 
or eradicate disease respectively (see table 2.3). 
Preventive vaccines are given to uninfected persons in order to elicit immune responses for 
protection against possible exposure to the infectious agent (Schoub, 2002). Thus, the most 
desirable outcome for HIV vaccines would be the prevention of infection, also known as 
sterilising immunity. However, most researchers concur that sterilising immunity through 
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candidate HIV vaccines is presently not feasible. Nonetheless, other significant results may 
also be derived. Thus while a vaccine may not prevent infection, it may prevent disease, 
delay progression of disease and decrease transmission of infection by significantly inhibiting 
viral replication (van Rensburg, 2002). Therapeutic vaccines on the other hand are 
administered to already infected individuals in order to elicit an immune response to 
accelerate recovery (Schoub, 2002). It is hypothesised that post-infection therapeutic 
vaccination may ameliorate disease by augmenting specific HIV immune mechanisms and 
simultaneously lead to a down-regulation of HIV replication in the body, although this still 
remains to be demonstrated (van Rensburg, 2002). The current study focuses on the prospects 
of a preventive vaccine rather than a therapeutic one. 
Live vaccines Killed (inactivated) vaccines 
Trivalent oral polio (TOPV) a) Whole organism 
Measles Diphtheria 
Mumps Pertussis (whole) 
Rubella Tetanus 
Yellow fever Trivalent inactivated polio (TPIV) 
Varicella Influenza (whole) 





Influenza (split-product & subunit) 
c) Recombinant 
Hepatitis B 
Table 2.2. Classification of vaccines (Adopted from Schoub, 2002, p. 562) 
Although extensive research has been underway for over 15 years and despite the successful 
history of effective vaccines against other viral infections there is still no effective HIV 
vaccine. HIV poses complexities in structure and the pathogenesis5 of infection that have 
made the development of a HIV preventive vaccine a mammoth task (Van Harmelen & 
Williamson, 2002). There is also much genetic diversity of HIV found world-wide, with over 
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10 genetic subtypes, or clades, of HIV-1 that have been characterised (IAVI, 1998), thus 
potentially limiting the applicability of a candidate vaccine from one region to another. 
Despite the challenges to vaccine development, increasing knowledge about HIV has 
benefited vaccine development and many of these challenges may be addressed in clinical 
trials over the next few years (Van Harmelen & Williamson, 2002). Furthermore, variability 
of HIV is being addressed through an expanded effort to develop vaccines for different 














Haemophilus influenzae b 
Hepatitis B 
Personal protection 




Table 2.3. Immunisation strategies (Adopted from Schoub, 2002, p. 562) 
HIV vaccine efforts have been underway since 1987. Significant scientific progress has been 
made, with both public and private sectors adding to the achievements (IAVI, 1998). In 
general government agencies play varied roles in vaccine research and development, 
including support of both basic and targeted biomedical research on the disease in question, 
development of clinical infrastructures, conduct clinical trials and train researchers (IAVI, 
1998). In South Africa the South African AIDS Vaccine Initiative (SAAVI), established by 
the government, has played an important role in coordinating the development of a local 
5 Pathogenesis - refers to the cause, development, and effects of disease (Rooney, 1999) 
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vaccine. S AAVI is essentially a multicentre multi-disciplinary programme managed by the 
Medical Research Council tasked with the goal of developing a safe, effective, affordable and 
accessible vaccine for South Africa by 2005. In addition, the initiative has a role to play in 
advocacy and education, and ethical considerations in vaccine development. SAAVI employs 
two primary approaches in executing its goals. The first is to produce a local more affordable 
vaccine for South Africa that would be country-specific and therefore, hopefully, more 
effective than products developed in other regions. The second approach entails active 
international collaboration. Researchers are working in earnest and it is planned that phase I 
trials with one or more subtype C candidates will start in 2003 (Galloway, 2000). 
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2.5.2. Challenges to the development of HIV vaccines 
In the search for an effective HIV vaccine numerous challenges have been encountered. 
Some of these are discussed below. 
2.5.2.1 Science and stages of testing 
The development and testing of a vaccine is a long and laborious task entailing complex 
biotechnology, research design, and complex ethical issues. While much scientific progress 
has been made the HIV virus provides challenges for researchers. These include: antigenic 
variation, the integration of viral genome into the host cells, correlates of protection are 
unknown and lack of a good animal model (van Rensburg, 2002). Nevertheless, this has not 
minimised hopes that an effective HIV vaccine will eventually be found. Traditionally, 
science has moved slowly and cautiously but the in the case of HIV vaccines there is pressure 
to move urgently but with diligence (Makgoba et al., 2002). 
In general, the goals for HIV vaccines are: to prevent infection, prevent or, delay progression 
of disease, and decrease transmission of infection (Abdool Karim, 2002). A preventive 
vaccine is tested on healthy human volunteers and conducted through successive phases 
(Esparza & Bhamarapravati, 2000). In a phase I trial a small number of healthy volunteers 
(10-20) is exposed to the candidate vaccine for the first time. In this phase the safety, 
maximum dose that can be tolerated, vaccination schedule, route of vaccination and immune 
responses are all investigated (Abdool Karim, 2002). Phase II trials usually enrol a few 
hundred volunteers. The objective in this phase is to assess the safety and immunogenicity, or 
optimal dose of the candidate vaccine - obtained in phase I using an 'at risk' population. 
Phase HI studies involve thousands of volunteers and test the efficacy of the vaccine using 
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the safe and immunogenic dose, route of administration and administration schedule obtained 
in phase I and II studies (ibid). Careful attention is also paid to possible side effects in this 
phase. In the final phase the vaccine reaches the market and its impact on the epidemiological 
pattern of HIV is measured. Post-marketing surveillance to identify adverse events present 
only in much larger numbers of people, would also be employed. Any vaccine has to go 
through this vigorous process before it can be considered effective. Thus, it may be at least 
ten years before an effective vaccine is developed and widely used in South Africa 
(UNAIDS, 2000). 
2.5.2.2 Political challenges 
Vaccine development is affected by both national and international politics. In a public 
address by the United Nations general secretary (2002) many African countries experience 
political instability, which often takes precedence over other important national issues, with 
HIV/AIDS de-prioritised. AIDS affects various regions differently. For efficient progress to 
be made all regions, regardless of socio-economic status, are obliged to work together. On the 
one hand, developed and rich countries have the expertise and experience to develop and test 
HIV vaccines but may not have large enough numbers of patients to conduct efficacy trials 
(Makgoba et al., 2002). On the other hand, most developing and poor countries do not have 
adequate infrastructure and resources to conduct large-scale trials (ibid). Therefore 
collaboration is appropriate. However, proper steps should be taken to ensure that ethical 
standards are upheld in these collaborative international research initiatives. A number of 
such initiatives have already begun to form. These include the Declaration of Commitment on 
HIV/AIDS, International AIDS Vaccine Initiative (LAVI) and its affiliated projects, the South 
African AIDS Vaccine Initiative (S AAVI), already discussed earlier, public-private 
partnerships, and many others. 
Furthermore, Makgoba et al. (2002) assert that most countries lack the political will and 
commitment to develop an HIV vaccine. This is reflected in inadequate relevant investment. 
In South Africa national government's stand appears to be equivocal, proclaiming support for 
the fight against AIDS and simultaneously entertaining dissident views. The salient issue of 
treatment for HIV infected people and AIDS sufferers' remains contentious, as there are 
currently no therapies being widely used in South Africa. Politicians have aired concerns 
about the long-term safety of antiretroviral drugs such as AZT and have questioned whether 
18 
adequate resources to control the epidemic are indeed available in South Africa. Conversely, 
many local AIDS activists and opposing political affiliates have voiced strong dissatisfaction 
with governments seemingly lack of urgency and decisive action in this regard. 
2.5.2.3 Economic challenges 
Developing countries bear the brunt of the AIDS burden. Poverty, poor infrastructure and 
poor access to basic health care services are typical of these countries. These countries are 
also affected by unemployment, crime, domestic violence, homelessness, and low education 
rates. AIDS is therefore a national priority among other competing needs. 
Thus, despite the challenges facing the development of an HIV vaccine, progress has been 
and continues to be made. Small-scale clinical trials of HIV-1 vaccines have been conducted 
since 1987 (Esparza & Bhamarapravati, 2000). Subsequently, larger-scale HIV-1 vaccine 
trials have been conducted in Europe, North America, Brazil, China, and Thailand. Phase I 
trials have been recently completed in Uganda and Kenya (Mugerwa et al., 2002). In 
addition, multicentre HIV phase HI trial have been conducted in Canada, the U.S., the 
Netherlands, Puerto Rico as well as in Thailand (VaxGen6,2003). The multicentre phase HI 
trials were completed at the end of 2002 and in February of this year (2003), VaxGen 
announced that the particular vaccine used did not prove effective in the trials conducted in 
North America and Europe. That is the study did not show a statistically significant 
reduction of HIV infection within the population as a whole, although statistically significant 
reduction of HIV infection in certain vaccinated groups (i.e. Black and Asian volunteers) was 
reported. Criticism in the media ensued about the statistical analysis of the non- Caucasian 
data. Subsequently, VaxGen presented further analyses of the phase HI data and stated that 
differences in vaccine efficacy observed between Caucasian and non-Caucasian volunteers 
could not have been due solely to chance (ibid). In South Africa preparations are well 
underway for a number of phase I trials. A concerted effort both nationally and 
internationally is paramount if South Africa is to succeed in this regard. 
In summary, the inadequacy of current interventions and high prevalence rates, limited 
treatment and preventive options, compel the need for an effective, safe and affordable 
6 VaxGen - a pharmaceutical developing prophylactic vaccines against HIV-1 consisting of two recombinant 
gpl20 surface proteins form different HIV-1 strains. 
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vaccine in collaboration with already established interventions. Schoub (2002) concludes that 
even vaccines with low efficacy could have a significant impact on the epidemic, although it 
is likely to be insufficient without permanent behaviour changes in the population. In 
addition, HIV has to be recognised as a health priority reflected by the finance and resource 
allocation by government, other stakeholders, and sponsors. A conducive environment for the 
development of an HIV vaccine should be enhanced by simultaneously targeting other social 
ills like poverty and access to basic health care services. 
2.6 Summary: Part 1 
The AIDS pandemic is increasing at a rate unmatched by any other pathogen (UNAEDS, 
2000). Although various interventions have been utilised to try and control it, these have 
proven inadequate (Harrison et al., 2000) and need to be further consolidated. In general, 
vaccination has been shown to be a safe, efficacious and affordable health intervention (Hall 
& O'Brien, 1998). The need for an HIV vaccine to complement current interventions has 
been recognised as both urgent and compelling (Barrett, 1998; IAVI, 1998; UNAIDS, 2000). 
There has been growing support for the development of HIV vaccine initiatives in sub-
Saharan Africa. Through the efforts of SAAVI, South Africa has emerged as a major role-
player in this regard and is due to begin with HIV safety trials later this year. However, the 
process involved in the development of an HIV vaccine is proving to be lengthy and 
challenging. Therefore the success of this project requires that good partnerships between 
various South African stakeholders as well as international collaboration be established, and 
that the numerous social, behavioural, and ethical challenges of trials be addressed. 
Chapter 2: Part 2: Ethical requirements for HIV preventive vaccine trials 
2.7 Protection of research participants 
2.7.1 Introduction 
While the need to develop a HIV vaccine is unquestionable, an equally important challenge is 
the protection of research participants who are enrolled in trials to test safety and efficacy. In 
general, clinical research aims to contribute to the social good by developing generalisable 
knowledge to improve health while minimising possible exploitation of research participants 
(Emanuel, Wendler & Grady, 2000). It is imperative therefore that ethical principles and 
standards are upheld during the process of vaccine testing. Complex social and ethical issues 
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associated with such trials are presented in the following section. However, before this 
discussion, it is important to recount the particular context from which biomedical research 
and ethics specifically has emerged. 
2.7.2 Cultural sensitivity within universal ethical principles 
In general, biomedical research on humans raises many ethical, legal and human rights 
concerns (UNAIDS, 2000; Wright, 1995). Over the years the application of biomedical ethics 
has developed as a field of study and various international ethical codes have been 
established. Noteworthy ethical references include: the Nuremberg Code of 1947, the 
Declaration of Helsinki of 1964 (revised in 2000), the World Health Organisation (WHO) 
and Council for International Organisations of Medical Sciences (CIOMS) guidelines drafted 
to confront transcultural7 issues and inequalities in research, and more recently a guidance 
document which specifically addresses international HIV preventive vaccine trials (UNAIDS, 
2000) and a discussion document which provides culturally sensitive guidelines for obtaining 
informed consent in HIV vaccine trials (Richter, Lindegger, Abdool Karim & Gasa, 1999). 
Developing countries have, on occasion, been the targets of ethical misconduct by researchers 
from more developed countries. Biomedical research in Africa has at times been 
characterised by an 'insensitivity' to the indigenous concerns of African countries, which has 
implications for future cooperation between western countries and developing countries 
(Lurie et al., 1994). For example, research conducted by French HIV vaccine researchers in 
Zaire in 1987, led to a perception that Africans served as "guinea pigs", and that "Western 
science often comes to Africa with "dirty hands" for clinical trials that would not be allowed 
in more developed countries (Christakis, 1988, p. 142). An AIDS vaccine trial in Africa 
should therefore be informed by ethical norms and cultural considerations prevailing in 
African settings (Christakis, 1988), and accommodate the social and economic realities 
therein (Abdool Karim, 2000b). This is a complex task, however, as there may be tension 
between international ethical principles versus those norms and practices present in an 
individual cultural setting. Therefore it remains the responsibility of all partners involved in 
the development of an HIV vaccine to address the ethical dilemmas that arise (Makgoba et 
al., 2002). 
7 Transcultural - " Transcultural research refers to clinical biomedical research that involves subjects and 
investigators from different cultures" (Christakis, 1996, p. 261, in Vanderpool, 1996). 
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South Africa has emerged from a particular political history that legitimised the systematic 
undermining of fundamental human rights, which has implications for HIV prevention 
vaccine research in South Africa. For example, many South Africans live under conditions of 
abject poverty and unemployment and this makes them vulnerable to abuse and exploitation. 
Researchers therefore have an obligation to protect the rights of 'vulnerable communities' 
(UNAIDS, 2000). Secondly, a distrust of 'modern' medicine may exist and African 
traditional medicine may be utilised. In particular, traditional healers are known to command 
a significant amount of support both in urban and rural black communities in South Africa, 
providing an alternative to the western medical paradigm. Conversely, idealisation of modern 
medicine may also exist. 
2.7.3 Ethical principles relevant to clinical research 
In essence ethics is a decision-making process about what is wrong or right (Abdool Karim, 
Q., 1997). Guidelines have been established in the form of codes of ethics (some mentioned 
earlier, e.g. The Nuremberg Code). Central to these guidelines are three universal principles 
namely, justice, beneficence/non-maleficence and autonomy (Slack et al., 2000). Justice 
refers to the fair distribution of research burdens/risks and benefits of which there are several 
widely accepted formulations (The National Commission of human subjects of biomedical 
and behavioural research, 1979). Formulations include: to each person an equal share, to each 
person according to individual need, to each person according to individual effort, to each 
person according to societal contribution, and to each person according to merit (ibid). With 
regards to research this has implications for the 'just' selection of participants. Beneficence is 
about maximising possible benefits of participation while non-maleficence refers to 
minimising possible harms. Autonomy refers to an individual's right to freedom of choice 
based on informed decision making. These fundamental principles are crucial to the conduct 
of all research. 
In addition, informed consent has remained a foundational principle of ethical research 
practice in clinical trials, since the publication of the Nuremberg Code (Lindegger & Richter, 
2000). However, the practice of requiring informed consent from research subjects has not 
always been adequately implemented. Despite the establishment of ethical codes in the 1940s 
and 1960s it was not until the 1970's that the practice of informed consent became 
conventional in the West (Ijsselmuiden & Faden, 1992). Generally, informed consent is 
usually seen as incorporating four essential components (Lindegger & Richter, 2000): 
22 
> Disclosure of all relevant information about the research 
> Comprehension by prospective participants of this information to make an informed 
decision 
> Freedom from all coercion of the prospective participant 
> Explicit and formal consent by the participant, usually in written form. 
2.7.4 Ethical issues relevant to HIV preventive vaccine trials 
It is complex to apply ethical principles in a standardised manner. For one, ethical guidelines 
could be interpreted differently across various situations. It has been argued that the 
numerous cultures exist globally for which certain principles may be culturally insensitive or 
inappropriate. Discrepancies in health care service and delivery in developed and developing 
countries may pose additional ethical challenges - the standard of care for example, may 
significantly differ. In this way while codes like the Nuremberg code, Declaration of Helsinki 
and Belmont Report have played a significant role in the west these may not be uniformly 
applicable for research in developing countries (Emanuel, Wendler, Killen & Grady, 2002). 
Research in developing countries must provide more than broad principles but must also 
confront unanswered ethical questions and stark disagreements (Emanuel et al., 2002). In 
1982, WHO in collaboration with CIOMS, drafted guidelines on how biomedical ethical 
principles could be applied more effectively in developing countries, taking into account 
culture, socio-economic circumstances, national laws, and executive and administrative 
arrangements. Similarly, another ethical guideline is the UNAIDS code of ethics, specifically 
for HIV vaccine trials. 
Although informed consent is necessary in most cases for clinical research to be deemed 
ethical informed consent is never sufficient on its own (Emanuel et al., 2000). Other ethical 
requirements comprise; that clinical research must be valuable, scientifically valid, selected 
subjects fairly, have a favourable risk-benefit ratio, must be subject to independent review for 
social accountability, and respect participants who have enrolled (ibid). 
Selection of participants in clinical trials must be fair and informed by predetermined criteria 
for inclusion and exclusion (Emanuel et al., 2000). According to UNAIDS (2000) guidelines 
for HIV vaccine research, Point 8, the choice of study populations for each trial phase should 
be determined and justified in advance by the scientific requirements and ethical challenges 
of each phase. As stipulated in 2.6.2.1 in phase I and phase II of HIV vaccine trials the goal is 
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to test the safety and dose optimisation, respectively. Therefore, generally participants are 
fewer and less vulnerable in the earlier phases (UNAIDS, 2000). However, in phase HI trials 
as the aim is to test the efficacy of the vaccine, a larger sample of people who are at risk is 
selected (UNAIDS, 2000), as this group of people would best answer the scientific question 
regarding the efficacy of the vaccine (Emanuel et al., 2000). Therefore while the participants 
are in a position to benefit if the research provides a positive result (e.g. if the vaccine is 
partially effective) they also bear the risks and burdens of the research. 
The fact that communities and individual participants qualify for phase IE trials on the basis 
of their HIV risk raises complex ethical considerations. Although the degree of risks and 
benefits is inherently uncertain in research, a favourable risk-benefit ratio needs to be 
consistently and carefully applied by endeavouring to minimise risks and enhance benefits 
(Emanuel et al., 2000; Emanuel et al., 2002). Furthermore, in keeping with the scientific aims 
of research fair selection of participants should ensure that benefits and burdens are 
distributed fairly (ibid). There is a potential conflict of interest for researchers in HIV 
preventive trials between reducing risk and measuring efficacy, and this necessitates that 
protective mechanisms for potential participants be put in place (Lurie et al., 1994). The 
interests of participants should always prevail over the interests of science and society, and 
this includes providing risk counselling and access to barrier methods to trial participants 
(Barrett, 1998). Community advisory boards need to be appointed and play an integral part in 
ensuring the rights of community members are protected, throughout the preparatory stages 
and trial phases (Abdool Karim, 2002). In addition, as prospective participants are also 
vulnerable to social discrimination and stigmatisation, should they seroconvert during the 
trial, participants need to be assured of confidentiality and other measures need to be put in 
place to minimise psychosocial risks. 
In South Africa HIV preventive vaccine trial sites have already been identified in kwa Zulu-
Natal and Gauteng (Tucker, 2002). In accordance with UNAIDS (2000) South Africa is 
justified to conduct its own HIV vaccine trials for the following reasons: 
> The high seroconversion rates in South Africa, which has made AIDS the biggest 
cause of death 
> Inadequacy of current HIV interventions coupled with poor access to antiretroviral 
therapies 
> The HIV-1 subtype C prevalent in South Africa and sub-Saharan Africa 
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> The resources and infrastructure South Africa has to host its own trials 
> The presence of a coordinated initiative (S AAVI) to ensure that South Africa has the 
scientific, ethical and logistical capacity to run its own HIV preventive trials. 
2.8 Preparation for HIV vaccine trials 
2.8.1 Introduction 
Preparation of host communities can be a challenging task, entailing detailed education 
campaigns and informed consent procedures. This is evident in the Ugandan experience of 
the first African safety trials where, despite elaborate preparations undertaken, myths and 
concerns arose among the general public and potential participants. Widespread rumours and 
conflicting media reports about the vaccine led to most of the confusion. Misconceptions 
included some mistaken beliefs that the vaccine was therapeutic and not preventive, a belief 
that the vaccine would protect against unsafe sex, fear that the volunteers would be injected 
with HIV, and fear that volunteers would be deliberately exposed to people infected with 
HIV (Mugwera, et al., 2002). 
Therefore before vaccine trials can take place extensive preparation is necessary to minimise 
the potential for confusion (described above). In general, vaccine preparedness encompasses 
the trial sites themselves and the broader community including prospective participants. 
Thus, the following section begins with what adequate preparation of the general public 
involves. A section follows it on meaningful and sustained community involvement of host 
communities. Finally, a section on adequate informed consent of prospective participants will 
be presented. 
2.8.2 Adequate preparation of general public 
From the onset the public needs to be informed about trials in a way that will not create high 
expectations of trial successes. For example, inadequately informed sources could 
sensationalise the process. A thorough widespread public information campaign however 
could attract potential participants and provide them with an opportunity to be educated and 
allay local concerns about the trial (Lurie et al., 1994). When dealing with mass media, it is 
essential not to exaggerate news or give ambiguous information. Such publicity could lead to 
polarising of public opinion, which could lead to a 'false sense of security' (Barrett, 1998; da 
Fonseca & Lie, 1995) on the one hand and scepticism on the other hand. False sense of 
security sentiments could encourage misguided beliefs that the vaccine is a cure for AIDS, 
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thereby leading to an increase in risky behaviour (Lurie et al., 1994). On the other hand, there 
is already a degree of stigmatisation surrounding ADDS (Department of Health, 1997, in 
Barrett, 1998) and sceptic sentiments could lead to decreased willingness to participate in 
trials. Both outcomes could impinge on the vaccine trial process. It is important that 
education campaigns and informed consent procedures be informed by both rigorous science 
and sound ethics. The media is also an invaluable partner in educating of the public. 
2.8.3 Meaningful and sustained community involvement 
As discussed in 2.7.4.2 community preparation is vital for HIV preventive vaccine trials. 
Accordingly, Point 5 of the UNAIDS (2000) guidance document alludes to three important 
considerations for community involvement in the preparation stages. Firstly, the involvement 
of community representatives should be based on an equal partnership. This implies that 
power should be shared between the community representatives and the extended research 
team, whereby both parties engage in a process of mutual education. Researchers have a 
significant role in explaining vaccines, how it may work and the trial process. Likewise, the 
community can inform researchers regarding health beliefs and cultural practices in the 
context of that particular community. The equal partnership also entails active involvement of 
the community representatives in the review, approval, and monitoring of HIV vaccine 
research. Secondly, the code suggests that open communication between the partners should 
be sustained in order to promote problem solving. Finally, community representation should 
be relevant and legitimate. That is, representatives should be determined through a process of 
broad consultation and appropriate representation. 
2.8.4 Preparation of host communities from which trial participants will be drawn 
Point 3 of the UNAIDS (2000) guidelines for HIV vaccine research reads: 
Strategies should be implemented to capacitate host countries and communities so that they 
can practice meaningful self-determination in vaccine development, can ensure the scientific 
and ethical conduct of vaccine development, and can function as equal partners with 
sponsors and others in a collaborative process. 
Similarly, Richter et al. (1999) suggest that volunteers should not only play an active role in 
the development of trials but should share in the decision making process with researchers, as 
well as community leaders (Abdool Karim, 2002). A community advisory board to represent 
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the interests of the community is also considered of paramount importance (ibid). Preparation 
of the host community includes education of the target population from which volunteers will 
be selected and preparing the community for large-scale HIV voluntary counselling and 
testing programmes (ibid). In educating the target population, researchers must ensure the 
appropriateness of the information, the method of presentation to enhance understanding, and 
must take into account demographic factors (such as age, gender and education) and attitudes 
toward the process (Silva & Sorrell, 1984). To facilitate this process of community 
preparedness adequate clinical infrastructure is also imperative (Abdool Karim, 2002; 
UNAIDS, 2000). 
2.8.5 Adequate informed consent 
Communities in developing countries are likely to be characterised by poverty, limited health 
care services, illiteracy and limited understanding of the nature of science which places these 
communities at increased risk of exploitation (Emanuel et al., 2002). Conducting research in 
developing countries makes the process of informed consent complex because of different 
languages, social traditions and practices (Emanuel et al., 2002). For example, in South 
Africa eleven official languages are recognised, which are accompanied by varied social 
tradition and practice. In general, informed consent is complex and sometimes an idealised 
process and often only fully understood by specialists (Lindegger & Richter, 2000). This has 
implications for HIV preventive vaccine trials given the complex information that must be 
transmitted. The question then becomes what constitutes "adequate informed consent" in 
developing countries. 
According to Emanuel et al. (2000) informed consent serves two purposes. Firstly, it serves 
to ensure that individuals control whether or not they enrol in clinical research. Thus, 
informed consent should be independent and steps should be taken to ensure that participants 
continue to understand and participate freely throughout the trial (WHO- CIOMS, 1993). 
Secondly, individuals may participate only when the research is consistent with their values, 
interests and preferences (Emanuel et al., 2000). Furthermore, informed consent should be 
based on complete, accurate and appropriately conveyed and understood information (WHO, 
1993). However, in reality many subjects are either incapable or limited in their capacity to 
give informed consent, including children, adults with severe mental or behavioural 
disorders, and many who are unfamiliar with modern medical concepts. In such cases special 
measures should be taken to protect these vulnerable individuals, which includes obtaining 
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proxy consent of a properly authorised representative and approval from an independent 
ethical review body (ibid). 
Furthermore, in practice there are many barriers to informed consent. Richter et al. (1999) 
summarise some of these barriers. Firstly, obtaining informed consent may be difficult 
because lay people often have problems remembering and understanding the details of 
scientific design and biomedical treatment comparisons. Secondly, prospective participants 
may experience defensive psychological forgetting of threatening information, especially 
about risks. Thirdly, obtaining informed consent may be difficult due to communication 
barriers emanating from cultural and class differences, including illiteracy, language 
differences, competing models of disease, and presumed differences in the construction of 
personhood. Fourthly, situational pressures, including a feeling of obligation may also 
complicate the process of obtaining informed consent. Fifthly, implicit forms of coercion 
may further complicate the process of obtaining informed consent by threatening 
voluntariness and the right to withdraw. Finally, health professional have to exercise restraint 
as they too have "vested interests". 
Emanuel et al. (2002) provide five benchmarks for fulfilling the principle of informed 
consent in developing countries: 
> Active community involvement in recruitment procedures and establishing incentives 
to facilitate appropriateness of the recruitment strategy. 
> Dissemination and disclosure of information should be sensitive to the local context 
and emphasise the role of collaborative partnership. This process must therefore take 
into account the language and cultural idioms, literacy and education levels, social 
practices, customs and culture of prospective participants. 
> Researchers must seek approval from the "spheres of consent" ranging from village 
elders to leaders of the extended family to heads of family. However, individual 
consent should not be supplanted by family or community consent. 
> Researchers should employ creative methods for documenting informed consent 
which could be verified by an independent observer and simultaneously culturally 
sensitive to the local context. 
> Researchers should give careful consideration to methods of ensuring that participants 
are able to refuse or withdraw from research without retribution. 
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2.9 Summary: Part 2 
"What is essential is not that the research meet the same ethical standard world-wide. What 
is essential is that the research manifest a culturally sensitive and ethically sophisticated 
concern for the well-being of subjects throughout the world" (Christakis ,1988, p. 142). 
In general, the planning and implementation of HIV preventive vaccine trials necessitate that 
due consideration be given to ethical standards and requirements. Although the establishment 
of ethical codes and guidelines has been extensive, in practice their implementation is 
challenging. Historically, three basic ethical principles have guided human research namely: 
justice, beneficence (non-maleficence) and autonomy (Slack et al., 2000). Informed consent 
has also been regarded as a foundational principle to clinical research and as such has 
received much attention (Lindegger & Richter, 2000). Increasingly though, researchers have 
recognised that informed consent on its own is insufficient and that clinical research further 
requires that: it be valuable, scientifically valid, select subjects fairly, have a favourable risk-
benefit ratio, be subject to independent review, and respect participants who have enrolled 
(Emanuel et al., 2000). Furthermore, extensive preparation of trial sites and participants is 
also required (Abdool Karim, 2002). At a community level, meaningful and sustained 
community involvement is essential to adequate preparation (Lurie et al., 1994; UNAIDS, 
2000). At an individual level, researchers must strive towards adequate informed consent for 
each trial participant. Psychologists have a role to play in informing both levels as well as in 
researching the expectations and perceptions of community members (Lindegger & Wood, 
1995). The current project for example, aims to explore knowledge and experiences with 
vaccination in general, and knowledge and expectations toward vaccination and participation 
in a hypothetical vaccine trial. The findings can then be used to inform education campaigns 
and informed consent procedures for HIV preventive vaccine trials as well as identifying 
areas for future research. 
Chapter 2: Part 3: Empirical review of knowledge, attitudes and predictors of 
immunisation behaviour 
2.10 Introduction 
To locate the current study within a body of literature the following section begins by 
describing vaccination as a health behaviour. This will be followed by a review of empirical 
studies of immunisation practices. A summary of studies that have looked at understandings 
and perceptions of vaccination is presented. Then studies investigating peoples' attitudes 
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toward vaccination are presented. In the final sub-section, peoples' willingness to participate 
in HIV vaccine trials, perceived barriers and incentives to participation, and social harm 
monitoring are discussed. 
In general vaccination programmes target specific subgroups of the population such as 
children, travellers and seniors although most extensive programmes have targeted children 
(Marks, Murray, Evans & Willig, 2000). Adult vaccinations usually encompass three types: 
work-related precautions (e.g. hepatitis B vaccination), vaccinations for 'at risk groups' (e.g. 
influenza vaccine) and vaccinations for overseas travel. A vast amount of research has been 
conducted in the field, the majority of which has focused on infant and child immunisation. 
Historically, mothers have had a significant role with regards to care giving in the home. 
Thus, mothers' knowledge and attitudes towards vaccination have been investigated widely. 
Predictors of vaccination compliance and completion, and barriers to vaccination have also 
been investigated to enhance immunisation programme implementation. 
Despite the relatively high uptake of immunisation programmes through the efforts of EPI 
there is a discrepancy in compliance rates with vaccination regimens. This is partially evident 
in the high rates of pneumonia and influenza deaths among the elderly and the increasing 
numbers of under-immunised pre-school children in the rural areas of the United States 
(Pruitt, Kline & Kovaz, 1995). 
Assuming that HrV vaccine trials may be seen as extensions of preventive health practices, as 
earlier mentioned in section 1.2, an investigation of general vaccination attitudes and 
experiences could prove helpful to the preparation for HIV vaccine trials (Slack et al., 2000). 
"The extent to which village and urban populations value being vaccinated can be understood 
only by determining their interpretations of disease and immunity, and past experience with 
vaccination..." (Greenough, 1995, p. 606). The current study explores knowledge and 
experiences of local students with vaccination. 
2.11 Immunisation as a health preventive behaviour 
Immunisation, which is administered to lessen susceptibility to debilitating and fatal disease 
(Gore et al., 1999) has been described as preventive health behaviour or a health protective 
practice (Gochman, 1998; Gore et al., 1999; Marks et al., 2000; Pitts, 1996; Slack et al., 
2000). Although therapeutic vaccines work differently, that is, they are administered after 
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exposure to the pathogen (Wood, 2002), the focus of the current study is on preventive 
vaccines in general and implications for HIV preventive vaccine trials. Preventive health 
behaviour can be defined as "those actions undertaken by persons who believe they are well, 
and who are not experiencing any signs or symptoms of illness, for the purpose of remaining 
well" (Gochman, 1988). Specifically, childhood immunisation is a preventive health 
behaviour that is directed toward the child by the parent (Gore et al., 1999). 
As one of the most successful methods of primary prevention of disease (Marks et al., 2000) 
immunisation is of great relevance to health psychology (Pitts, 1996). Despite 
immunisation's proven efficacy, its uptake varies over time and place (Marks et al., 2000). 
Psychology offers models that aim to understand the various social and psychological factors 
associated with uptake, and yet psychologists have little to say about this particular health 
behaviour (Pitts, 1996). However, an understanding of preventive health behaviour is 
becoming increasingly important to health care providers in general (Gore et al., 1999). 
Health psychology researchers have posited numerous frameworks to study and intervene in 
preventive health behaviour. The frameworks used have been primarily based on decision-
making theory and attitude theory, with an emphasis on socio-behavioural components (ibid). 
These frameworks include: the health belief model, the theory of reasoned action, illness 
representation model, protection motivation model, the transtheoretical model and the 
precaution adoption process model (Pitts, 1996). While these models generally explicate the 
factors involved in developing and changing people's health behaviours, these models have 
also been criticised for focusing on the individual, at the cost of other factors (ibid). For 
example economic, social, political and environmental factors also have an impact on health 
behaviours, such as immunisation uptake. 
Pitts (1996) posited the following about the psychosocial aspects of vaccination. Firstly, he 
identified a clear link between health knowledge and the likelihood of vaccination. Secondly, 
demographic variables, particularly in developing countries, also add to understanding 
vaccination behaviour. Finally, perceptions of risk, including on behalf of others, are also 
important predictors of immunisation uptake, strongly influenced by media campaigns and 
personal experience (ibid). In the current study knowledge and experiences with vaccination 
are explored and their association with particular demographics. 
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2.12 Knowledge and perceptions about vaccination 
2.12.1 Introduction 
The following sub-section begins with a summary of empirical studies investigating 
knowledge about vaccination, followed by misconceptions about vaccination. A review of 
literature in this field indicates that knowledge is defined and measured differently. Formal 
measures, like knowledge of EPI, have been consistently used to identify various components 
of knowledge across different studies. The scope of the current review is not exhaustive. 
2.12.2 Studies investigating knowledge of vaccines 
In Italy a study was carried out with 841 mothers through self-administered questionnaires. 
The mothers of 841 infants were randomly selected from a representative cross-section of 
various kindergartens (which their children attended) from two towns. Among other things, 
the study evaluated the knowledge of mothers about vaccine-preventable diseases. The results 
showed that both age and education levels were significantly related to knowledge about four 
mandatory vaccinations for infants. In general, mothers who were older at the time of the 
child's birth were more knowledgeable than younger mothers about vaccination. Similarly, 
mothers with higher education levels knew more about vaccination than mothers with lower 
education levels. Mothers knew most of the mandatory vaccinations and rightly reported 
vaccinations for hepatitis B (87.5%), poliomyelitis (79.9%), tetanus (74.4%) and diphtheria 
(66.3%), respectively. About half of the sample (45.2%) correctly believed that the 
undesirable side-effects of vaccinations are a important determinant of their value. Reported 
sources of information about vaccination were from paediatricians (70.2%), mass media 
(30.3%), pamphlets (24.1%), and family physicians (19.7%), respectively. Most of the 
mothers (81.5%) wanted to learn more about various aspects of vaccines and the diseases 
they prevent (Angelillo et al., 1999). 
In China, Zhang, Wang, Zhu & Wang (1999) conducted a vaccination survey to provide 
baseline information for a health education program. Thus, the care-takers of 2520 children 
were randomly selected from 12 counties. Although the vast majority of the parents (98.4%) 
believed that immunisation plays a role in preventing diseases the results revealed that the 
level of EPI knowledge in general was poor. Only 58.2% had knowledge about measles 
infections. Most parents had also had to be reminded by the health providers to vaccinate 
their children. All parents had confidence in their providers and 92.7% had received health 
knowledge from their providers. The mothers' EPI knowledge was strongly associated with 
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mothers' educational level, family socio-economic status, health insurance schemes for 
immunisation services and the frequency of watching TV or listening to radio. It was also 
found that the level of EPI knowledge among parents was positively associated with their 
attitude to and practices of vaccination. 
In Africa, another study was conducted in Ethiopia on immunisation uptake and identification 
of problems associated with vaccination delivery (Gedlu & Tesemma, 1997). A cluster-
sample survey of 1269 households in Gondar town was undertaken. The care-takers of 213 
children aged 12-24 months were sampled. Again most of the respondents (91.7%) reported 
that immunisation protects against diseases. These findings were similar to those reported 
from research conducted in Keffa, south west Ethiopia, and India (ibid). No significant 
differences were found between the level of knowledge and demographics. In addition, 
despite the level of knowledge of protective nature of vaccines, uptake of immunisation was 
low. The authors concluded "that both knowledge and motivation to return regularly with the 
child are vital in increasing immunisation coverage" (Gedlu & Tesemma, 1997, p. 241). 
In another study in eastern Zimbabwe seven focus group discussions were conducted with 43 
mothers in Chimanimani District after a measles outbreak in 1986 (Razum, 1993). All 
mothers had at least one child under the age of five years and were selected with the 
assistance from either local teachers or village workers. In addition, mothers waiting at the 
district hospital were also recruited for one session. The focus group discussions ran in 
parallel with a survey of the Expanded Programme on Immunisation (EPI). Six leading 
questions directed the focus group discussions. Questions investigated knowledge, beliefs and 
perceived consequences of immunisation. These included questions around mothers' 
perceptions of vaccination in general as well as questions on perceived side effects of 
vaccination. Results revealed that mothers were informed about immunisation but low uptake 
of services was mainly due to the poor quality of EPI services. No demographic 
characteristics were explored in this particular study; except that the sample was drawn out of 
a rural population. 
In a local study conducted in Cape Town, Van Staden, Langenhoven, Dhansay, Laubscher & 
Benade (1995) investigated mothers' knowledge about immunisation and other child health 
care promotion processes. A cross-sectional study was done on a random sample of 267 
mothers with children aged 0-24 months attending a child health clinic (CHC). A 
questionnaire was administered comprising of questions on socio-demographic information 
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and other child health care prevention packages. Most mothers (92%) stated that 
immunisation was to prevent diseases while 8% were unsure. Mothers' knowledge about 
which diseases their children were being immunised against was as follows: measles 
relatively high (77%) and TB moderate (43%). Few mentioned polio and chicken pox, and 
none knew about polio while 9% could not name any disease. The researchers concluded that 
mothers' knowledge about the diseases for which immunisation were given was inadequate. 
In particular, single mothers who were younger than 25 years and who delivered a low birth-
weight baby, had the poorest knowledge levels. 
In Hlabisa, kwa Zulu-Natal, South Africa, a study on maternal and child health indicators in 
the rural South African Health District was carried out on 480 mothers (or carers) of children 
aged 12-35 months (Wilkinson, Cutts, Ntuli, & Abdool Karim, 1997). Cluster sampling was 
used to select participants. A questionnaire on antenatal care attendance and the child's 
immunisation status was used. It was found that overall immunisation uptake was high (80-98 
%). However, from this number, only 76% had received all the vaccines needed for a 12 -
month old child, and only 88% of these had received all doses by 12 months of age. Up to 
83% had neither experienced nor heard of an adverse reaction to immunisation (ibid). 
2.12.3 Misconceptions about vaccination 
Immunisation has been frequently demonstrated, in both research trials and in measurements 
of efficacy made in the field, to be one of the most effective available medical interventions 
to prevent disease. It has been approximated that immunisations currently save three million 
lives per year throughout the world while remaining one of the most cost effective health 
preventions, providing high levels of protection against certain diseases and consequent 
disability and death (Hall & O'Brien, 1998). 
Despite these obvious benefits there are those who have reservations about immunisation and 
its efficacy. These objections include religious or philosophical reasons. Furthermore, 
misconceptions exist about the safety and efficacy of vaccines. Six common misconceptions 
about vaccination are listed below (Hall & O'Brien, 1998; Pless, n.d.). 
One misconception that exists is that human survival rates have improved due to better 
nutrition and other treatments such as antibiotics, and that vaccines are proving to be 
increasingly redundant and unnecessary. A second misconception is that vaccines are not 
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effective and that most vaccinated persons contract the disease despite being previously 
vaccinated. Another related misconception is that vaccines are not safe, causing harmful side 
effects including death. Fourthly, another myth is that vaccines actually cause illness and 
possible long-term effects. Yet another belief is that vaccines are no longer needed as the 
respective disease have been eliminated. A final misconception is that the giving of various 
combinations of vaccines simultaneously increases the risk of harmful side effects and 
compromises the immune system. Angellilo et al.(1999) reported in their study some 
misunderstandings about which vaccinations were mandatory and some participants 
overestimated the requirements for their children. Gedlu & Tesemma (1997) in their study 
found that certain participants were under the misconception that disease is better than 
vaccination, while others believed that vaccines actually cause illness. 
In summary, measurement of knowledge has varied across studies, allowing for many 
knowledge components to be investigated. These different measures include: knowledge of 
and correct use of vaccine regimens (Angelillo et al., 1999; Van Staden et al., 1995; 
Wilkinson et al., 1997), adverse and side effects of vaccines (Angelillo et al., 1999; 
Wilkinson et al., 1997), the purpose of vaccination (Gedlu &Tesemma, 1997; Van Staden et 
al., 1995; Zhang et al., 1999), reported sources of information (Angelillo et al., 1999; Zhang 
et al., 1999), and confidence in health providers (Zhang et al., 1999). The distinction between 
general and specific knowledge has not been explored across the various studies. For 
example, while general knowledge about how vaccines work has been explored specific 
knowledge about the role of the immune system and how it works has not been widely 
explored. This is important because it has implications for what constitutes an adequate level 
of knowledge in education campaigns and informed consent procedures for future HIV 
vaccine trials. 
In general, however it would appear that knowledge of vaccination systematically varies 
according to age (Angelillo et al., 1999; Van Staden et al., 1995), education (Angelillo et al., 
1999; Zhang et al., 1999), socio-economic status, access to health insurance schemes, and 
exposure to information sources (Zhang et al., 1999). However, other studies have found no 
significant differences between the level of knowledge and demographics of the participants 
(Gedlu & Tesemma, 1997; Razum, 1993). It would further appear that knowledge on its own 
is not a reliable determinant of vaccination practice. The latter appears determined also by 
other factors, for example motivation to vaccinate (Gedlu &Tesemma, 1997), quality of 
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immunisation service (Razum, 1993), and attitude toward vaccination and practices of 
vaccination (Zhang et al., 1999). It is also evident that misconceptions or 'negative' 
knowledge about vaccines are present (Hall, 1998; Pless, n.d.) and studies support this 
(Angelillo et al., 1999; Gedlu & Tesemma, 1997). 
2.13 Attitudes toward vaccinations 
2.13.1 Introduction 
Literature on attitudes toward vaccines indicates that attitudes tend to be associated with a 
value component, on a continuum of positive and negative attitudes. Thus, these studies often 
utilise various Likert scales. Attitudes also appear to play a mediating role between 
knowledge and experience. That is, peoples' attitude towards vaccines appears to be related 
to their level of knowledge and previous experiences with vaccines. In this section, the results 
of studies that have investigated attitudes toward vaccination will be discussed. 
2.13.2 Studies on attitudes toward vaccination 
In Kerala, India a study was carried out by Raman Kutty (1989) in which 78 rural mothers 
were interviewed. The purpose of the study was to find out the relationship between women's 
education and its influence on attitudes to various aspects of childcare; including child health 
status awareness, breast-feeding, and immunisations. All mothers were given 50 statements to 
which they responded 'agree', 'disagree' or 'don't know'. The results showed a general 
positive attitude toward vaccination. However, stronger positive attitudes toward traditional 
aspects of childcare (such as breast- feeding) were found than toward immunisation. That is, 
although people generally held vaccinations in a favourable light, the more traditional aspects 
of childcare were more favoured. No significant differences between educated and less 
educated women in terms of attitudes toward vaccination were reported. One interesting 
finding from the former study was that husband's education was found to have positive 
impact on women's attitudes toward vaccination (Raman Kutty, 1989). That is, in households 
where husbands were more educated, their wives tended to hold more positive attitudes 
toward vaccination than those with less educated husbands. 
In a study with 841 mothers who completed self-administered questionnaires, Angelillo et al. 
(1999) also assessed mother's attitudes toward vaccinations of infants. All questions about 
attitudes were scored on either a three-point Lifetreescale with options for "agree," 
"uncertain," or "disagree" or on a 10-point Likert scale for attitudes on the utility of 
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vaccinations. They found that in general attitudes toward the use of vaccinations for 
preventing infectious diseases were very favourable. No significant differences in attitudes 
were found for socio-demographic characteristics. However, low education of parents was 
associated with non-adherence to vaccination. 
In another study in Ile-Ife, Nigeria, 200 mothers were interviewed (Odebiyi, & Ekong, 1982). 
Initially, an areal probability sampling technique was used in which areal units were defined 
by grid squares superimposed on a map of Ile-Ife town. From a total of 50 grid squares, 10 
squares were randomly selected from which further blocks were obtained and systematically 
sampled so that one out of every two blocks was selected from each square. Eligible 
households were selected. Mothers' concept of measles and attitudes towards the measles 
vaccine were investigated. The results found that the attitude of Nigerian mothers towards 
vaccines and other aspects of prevention are influenced by different perceptions of the cause 
of measles. A significant correlation between the literacy of mothers and their belief in the 
efficacy of measles vaccine was found. For example, eighty-one of the 103 non-literate 
mothers believed that the vaccine was not preventive because they claimed that some of their 
children who had been immunised still contracted measles. The mothers' perception of 
measles vaccine was also found to be a function of their socio-economic characteristics, with 
the lower socio-economic group favouring a supernatural explanation for measles (ibid). 
In short, various studies have been carried out specifically investigating mothers' attitudes 
toward vaccination. These studies have examined mothers' general attitude toward vaccine 
safety, efficacy and service delivery in an open-ended manner while others have focused on 
particular attitudes using Likert-type scales. In general, positive attitudes toward vaccination 
were reported. This would contradict research conducted by Nichter (1995) that identified 
negative attitudes toward vaccination. Opposition to vaccination in the latter study included 
suspicion of hidden political agendas, and perceptions that poverty relief, delivery of basic 
services and other important health needs could be sidelined or given less attention as a 
result. 
2.14 Predictors of, and barriers to, immunisation 
Other predictors to immunisation have also been reported. These are enumerated below. 
Greenough (1995) purports that the acceptability of or non-compliance with vaccination is 
non-random. In developing countries non-compliance reportedly varies mainly according to 
sect and ethnicity, although class, caste, gender, age, geography and literacy are also notable 
sources of differentiation (Greenough, 1995). Numerous vaccination studies have been 
conducted which have explored both predictors and barriers to vaccination, depending on the 
researchers interest. It can be deduced that predictors and barriers are 'two sides of the same 
coin', and are therefore discussed simultaneously. 
Positive health beliefs have been positively related with vaccination. For example, Markland 
and Durand (1976) reported that adequately immunised populations have been shown to 
possess a high perception of disease seriousness and risk of disease. Adequate knowledge of 
vaccine efficacy, adequate knowledge of length of protection afforded by vaccine, and greater 
media exposure have been shown to be positively related with immunisation (Markland & 
Durand, 1976). Demographic factors such as: rural dwelling (Akesode, 1982; Edpuganti, 
2000; Zurayk & Gangarosa, 1982), bigger families (Markland & Durand, 1976), low socio-
economic status (Odebiyi & Ekong, 1982; Streatfield & Singarimbum, 1988), low education 
(Akesode, 1982; Edpuganti, 2000; Zurayk & Gangarosa, 1982), younger parental age 
(Markland & Durand, 1976) have been identified as potential barriers to vaccination. Cultural 
and religious beliefs and practices also have an impact on immunisation behaviour (Odebiyi 
& Ekong, 1982). These practices have been used in conjunction with immunisation (Eng, 
Naimoli, Parker, Lowenthal, 1991; Odebiyi & Ekong, 1982). Finally, Greenough (1995) also 
points out despite the effective vaccine technology, style and continuity of vaccination 
service is also important. 
2.15 Participation in HIV preventive vaccine trials 
2.15.1 Introduction 
In this section, the results of selected studies that have looked at health beliefs and attitudes 
toward HIV vaccination and participation in trials of HIV preventive vaccines will be 
presented. 
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2.15.2 Understandings of trial participation 
Assessment of willingness to participate (WTP) in hypothetical HIV preventive vaccine trials 
can help identify educational issues necessary for adequate informed consent procedures and, 
in addition, provide information on the level of recruitment needed to achieve adequate trial 
enrolment. In a guide prepared for UN AIDS MacQueen (1999) puts forward several 
informational requirements including: basic elements of trial design, vaccine concepts, 
medical risks, social risks, behavioural risk reduction, benefits of participation and trial 
sponsorship. 
Numerous studies on WTP and related subjects have emerged since the early 1990s 
(MacQueen, 1999). These studies have yielded differing degrees of understanding of HIV 
vaccines and clinical trials among the participants (Bartholow et al., 1997; Koblin et al., 
1998; McGrath, George, et al., 2001; McGrath, Mafigiri, et al., 2001; Ross, Jeffords & Gold, 
1993). In Uganda, where the first safety trials in Africa were conducted, McGrath, George, et 
al. (2001) and McGrath, Mafigiri, et al. (2001) found that participants in a vaccine 
preparatory study were familiar with vaccines but did not clearly distinguish the use of 
vaccines for prevention or curing, trial procedures were unfamiliar (e.g. placebos, 
randomisation, and blinding) and knowledge about trial procedures increased incrementally 
over follow-up. This again highlights the importance of appropriate dissemination of 
information repeated over time as this has direct implications for education campaigns for 
host communities and informed consent procedures for potential trial participants. 
2.15.3 Attitudes: Willingness to participate (WTP) 
WTP in a preventive vaccine trial is hypothesised to be a complex interaction of different 
factors in a person's life including: perceived risk of HIV infection due to behavioural and 
environmental factors; perceived risks of participating in the trial; perceived benefits of 
participating in the trial; comprehension of how the trial works; trust in those implementing 
and supporting the trial; altruistic motivations; and peer influence (MacQueen, 1999). The 
many studies conducted on WTP have been among female commercial sex workers and STD 
patients in northern Thailand (Celentano et al., 1995), injecting drug users in the United 
States (MacQueen et al., 1999; Fureman, Meyers, McLellan, Metzger & Woody, 1997, in 
MacQueen, 1999) heterosexual men and women in San Francisco (Chesney, Chambers & 
Khan, 1997, in McGrath, George, et al., 2001) and in Kenya (Jackson, Martin, Bwayo et al., 
1995, in McGrath, George, et al., 2001), men who have sex with men (MSM) (Koblin, et al., 
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1998) and male soldiers in Uganda (Horn, Johnson, Mugyenyi et al., 1997, in McGrath, 
George, etal., 2001). 
MacQueen (1999) presents a systematic review of literature of studies conducted in America 
and Thailand from 1990s to 1998. MacQueen (1999) deduced the following from the various 
studies: 
> WTP ranged from 20% to 50%, 
> Those not WTP ranged from 3% to 9%, 
> The primary incentives for participation were altruism and opportunities for reducing 
one's personal risk for HIV infection, and 
> Potential barriers to trial participation included concerns about vaccine side effects, 
the potential for vaccine-induced HrV infection and accelerated progression to AIDS, 
duration of the trial, distrust of researchers and government, and social consequences 
of vaccine-induced seropositivity and trial participation. 
In the following section, two studies that have explored acceptability of an HrV vaccine 
specifically among students will be presented. 
A study of 125 undergraduate students from an urban Midwestern University in the USA who 
volunteered for research as a means of fulfilling requirements of introductory psychology 
courses was conducted (Zimet, Liau & Fortenberry, 1997). Self-administered questionnaires 
were distributed. The purpose of the study was to evaluate the relationship of health beliefs to 
the intention to accept an HIV vaccine. Health beliefs such as perceived susceptibility to 
HIV, perceived severity of ADDS, benefits associated with receiving hypothetical HIV 
vaccination and barriers to performance of health behaviour were assessed. The 
questionnaire also elicited socio-demographic information such as age, gender and race. 
Intention to get vaccinated was not significantly related to gender or race. These results 
would appear to contradict studies that have shown that African-Americans are particularly 
distrustful of science and policy as they relate to AIDS. While intention to vaccinate was 
marginally associated with age, the relationship between intention to vaccinate and age was 
not a significant one. Results revealed that higher levels of perceived susceptibility, perceived 
severity, benefits and lower levels of barriers (such as fear of the vaccine and fear of needles) 
were related to greater willingness to get an HIV vaccine. Thus, it may be concluded that 
40 
intention to accept or reject an HIV vaccine is not universal but depends on a number of 
factors, including context (Zimet, et al., 1997). 
Zimet, Fortenberry & Blythe (1999) conducted a study with 318 adolescents in Indianapolis, 
USA. The study evaluated associations of health beliefs and health behaviours with attitudes 
to HIV immunisation. The sample of adolescents was recruited from urban community health 
clinics when they were receiving healthcare. All participants were given an anonymous self-
administered questionnaire, which they completed in a waiting room of the medical clinic 
while awaiting an appointment. Demographic variables included age (13-18), gender, race/ 
ethnicity (African American, non-Hispanic, White, Hispanic and other). The results indicated 
that adolescents who practised less health behaviours were more open to the idea of an HIV 
vaccine than those who engaged in more health protective behaviour. More specifically, those 
people that used condoms less frequently, and were therefore at higher risk, were more 
accepting of HIV immunisation than people who exercised health protective behaviours. 
Several beliefs associated with non-acceptance were: low perceived vulnerability to infection, 
doubts about vaccine efficacy; worries about vaccine safety; and fears about getting 
injections (Zimet, et al., 1999). Such health beliefs were important in informing participants' 
attitudes to HIV vaccination, and impacting on their hypothetical intentions to vaccinate or 
not. These findings highlight the importance of health beliefs in influencing the acceptance of 
HIV immunisation. 
2.15.4 Behavioural studies: Social harm monitoring 
HIV preventive vaccine trials have the potential for psychosocial risks (UNAIDS, 2000). For 
example, volunteers may test positive on standard HIV tests and subsequently face 
stigmatisation and prejudice by those who mistakenly consider these volunteers to be either 
HIV infected, as having AIDS, or identifying the volunteers as being in a risk group 
(MacQueen, 1999; UNAIDS, 2000). Thus, it is important that social harm is monitored 
during and after vaccine trials. In one study (Allen et al., 2001) 1516 AIDS Vaccine 
Evaluation Group (AVEG) volunteers were questioned about trial-related discrimination 
(TRD). From this total seventy-six participants (5%) reported TRD events. Of these the most 
cited incidents were negative reactions of friends, family, and co-workers while a few were 
related to HIV testing. Furthermore, the majority of events were ultimately resolved while 
40% were not. On the whole the findings indicated that TRD was neither widespread nor 
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severe. It is therefore important that researchers ensure that social harm is monitored in 
prospective trials as TRD may vary across different studies and contexts. 
In summary, numerous studies have been carried out specifically looking at attitudes towards 
HIV vaccine trials and participation therein on different groups of people, including 
commercial sex workers. This field of research has come to be known as willingness to 
participate (WTP). In this field of research an educational component precedes formal 
assessment of WTP, which is considered as both imperative and a more valid way of 
assessing WTP (MacQueen, 1999). WTP in a HIV preventive vaccine trial has been regarded 
as a complex process, which needs to be adequately measured (ibid). In general the findings 
across the different studies have varied with WTP ranging from 20 % to 50%, those not WTP 
ranged from 3% to 9%, primary incentives for participation were altruism and opportunities 
for reducing one's personal risk for HIV infection. Potential barriers to trial participation 
included concerns about vaccine side effects, the potential for vaccine-induced HIV infection 
and accelerated progression to AIDS, duration of the trial, distrust of researchers and 
government, and social consequences of vaccine-induced seropositivity and trial 
participation. 
2.16 Summary: Part 3 
Immunisation, which has been described as a preventive health behaviour (Gochman, 1988; 
Gore et al., 1999; Marks et al., 2000; Pitts, 1996) is becoming increasingly important to 
health providers including Psychology (Gore et al., 1999; Pitts, 1996). Health psychology has 
posited various models to study and intervene in preventive health behaviour, primarily 
drawing on decision-making theory and attitude theory (Gore et al., 1999). Numerous studies 
have been conducted that have explored various aspects of immunisation, the majority of 
which have focused on childhood immunisation. As a result mothers knowledge and attitudes 
towards vaccination have been widely investigated and were of main focus of the current 
empirical review. In general, measurement of knowledge has varied across studies, allowing 
for many knowledge components to be investigated. These different measures include: 
knowledge of and correct use of vaccine regimens (Angelillo et al., 1999; Van Staden et al., 
1995; Wilkinson et al., 1997), adverse and side effects of vaccines (Angelillo et al., 1999; 
Wilkinson et al., 1997), the purpose of vaccination (Gedlu &Tesemma, 1997; Van Staden et 
al., 1995; Zhang et al., 1999), reported sources of information (Angelillo et al., 1999; Zhang 
et al., 1999), and confidence in health providers (Zhang et al., 1999). Generally, it would 
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seem that knowledge of vaccination varies according to age (Angelillo et al., 1999; Van 
Staden et al., 1995), education (Angelillo et al., 1999; Zhang et al., 1999), socio-economic 
status, access to health care insurance schemes, and exposure to information sources (Zhang 
et al., 1999). Generally, mothers reported positive attitudes toward vaccination (Angelillo et 
al., 1999; Raman Kutty, 1989). Regarding HIV preventive vaccine trials WTP has been said 
to involve a complex interaction of different factors in a person's life and has been reported 
to range from 20% to 50% (MacQueen, 1999). Although research conducted on 1516 
Vaccine evaluation Group (AVEG) volunteers on trial-related discrimination (TRD) has 
suggested that on the whole TRD was neither widespread nor severe, this may vary across 
different studies and contexts. In South Africa, social discrimination on the basis of HIV 
status is known to be high (Department of Health, 1997 in Barrett, 1998) and therefore 
monitoring of social harm of potential participants is imperative. 
2.17 Summary: Literature review 
At the turn of the twentieth century the AIDS pandemic poses a great threat to human life in 
South Africa, stretching limited health resources to their limits. With current interventions 
yielding limited results against the AIDS crisis (Harrison et al., 2000) a HIV vaccine has been 
proclaimed as compelling and urgent both worldwide and within Southern Africa (Barrett, 
1998; IAVI, 1998; UNAIDS, 2000). An HIV preventive vaccine would complement and 
reinforce already established AIDS interventions and would require international and national 
cooperation for its effective implementation. Through the coordinated efforts of SAAVI, 
South Africa is due to start its first HIV safety trials this year. However, clinical trials 
generally require rigorous implementation and monitoring of research ethics (Emanuel et al., 
2000) and extensive preparation, including education campaigns, informed consent 
procedures and social science research (Abdool Karim, 2002). Through the many projects 
coordinated by SAAVI, these issues are being addressed. Many research projects have been 
conducted worldwide that have explored attitudes and behaviour with regards to vaccination 
in general and these have yielded differing results. More recently, with the advent of HIV 
preventive vaccine trials WTP, perceived barriers and incentives to trial participation 
(MacQueen, 1999) have been increasingly the focus of study. In South Africa, however, 
information regarding vaccination in general is sparse. 
Psychology as a discipline has a significant contribution to make towards AIDS intervention 
including: policy development; preventive education campaigns; education and training of 
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lay counsellors; psychological counselling for screening and for HIV-affected people, their 
families, co-workers and carers; psychological services for the 'worried well'; assisting with 
training of health care workers; and conducting ADDS related research (Schneider, 1989 in 
Lindegger & Wood, 1995). In conjunction with a series of studies (da Silva, 2003; Lindegger, 
et al., 2003) the current study set out to investigate knowledge and experiences of vaccination 
in general, and knowledge of and expectations toward HIV vaccination and participation in a 
hypothetical vaccine trial, among students, as part of the national preparation for HIV vaccine 
trials in South Africa. 
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Chapter 3: METHODOLOGY 
3.1 Introduction 
The following chapter presents the methodology used in the study. The study set out to 
explore local students' knowledge and experiences with vaccination in general, and attitudes 
toward possible participation in HIV preventive vaccine trials as part of national preparation 
for HIV safety trials in South Africa. This chapter presents with a description of the research 
design, which provides a framework for the rest of the chapter, where the different research 
design components are described sequentially in the following order: key objectives, 
sampling procedure, measures and data analysis. 
3.2 Research design 
Research design can be described as the coherent framework between the research aims and 
questions, strategic methods used including sampling techniques, measures and data analysis 
(Terre Blanche & Durrheim, 1999). Applied research is mostly atheoretical, in that it is not 
necessarily guided by an established paradigm or model (Denzin & Lincoln, 1994). In this 
sense the current study was not held by a specific set of theoretical assumptions, instead the 
study was exploratory in nature (Neuman, 2000). As mentioned in section 1.2 very little 
research has been conducted in South Africa on peoples' knowledge and experiences with 
vaccination in general contrasted with numerous studies conducted worldwide. The 
researcher, therefore, attempted to broadly explore these phenomena within a South African 
context, and specifically a student population, and in so doing formulate more precise 
questions for future research (Terre Blanche & Durrheim, 1999). While the research was 
driven by specific aims, the particular research questions were refined as the research process 
unfolded (ibid) and the researcher sought a deeper understanding of the subject matter. 
3.3 Key objectives of current study 
As part of a larger vaccination study (da Silva, 2003; Lindegger et al., 2003) being carried out 
in the country, the current study broadly set out to survey student attitudes to vaccination in 
general, in preparation for preventive HIV vaccine trials (Slack et al., 2000). The current 
study is based on the premise that given South Africa's longstanding history with vaccination 
as a form of preventive practice, student understandings and experiences with vaccination 
could be investigated. This could form part of the preparation for HIV preventive vaccine 
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trials by informing education campaigns and informed consent procedures. In addition this 
study attempted to add to the body of empirical literature locally, as information in this regard 
is sparse in South Africa, and to generate more precise questions for future research. Thus, 
the key objectives of the present study were to assess students': 
1. Understandings of vaccination: Knowledge and perceptions of vaccination in general, 
including perceived barriers to vaccination. Specifically the following aspects of 
understanding were assessed; 
> Knowledge of the purpose and mechanism of vaccination, 
> Knowledge of vaccine - preventable diseases, 
> Knowledge of various perceptions about vaccination in general, including barriers 
to vaccination, 
2. Experiences of vaccination generally; 
> Specifically students' experiences with vaccination and the uses of vaccination, 
3. Knowledge of and expectations toward HIV vaccination and participation in a 
hypothetical vaccine trial; and 
> Specifically, awareness about the pending HIV preventive vaccine trials, 
perceived purpose and target of such trials, 
> Perceptions about participation in a hypothetical vaccine trial, and 
> Perceived incentives and barriers for participation, 
4. To explore if particular knowledge and experiences are associated with demographics 
such as motherhood and gender. 
> Specifically, the association between certain aspects of knowledge and 
experiences, and demographics such as gender and motherhood was explored. 
In terms of objective 4 it was assumed that mothers would be more knowledgeable and 
provide more information and rich explanations, having had more recent and continued 
contact with vaccination. 
This research was part of a larger study, which aimed to assess: i) local or popular 
understandings, perceptions and barriers to vaccination; ii) culturally and traditionally based 
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images, metaphors and beliefs surrounding vaccination, and the impact of these on attitudes 
to vaccination; iii) Knowledge about potential HIV vaccines and attitudes to participation in 
HIV vaccine trials among a number of sub-samples, including clinic attenders (da Silva, 
2003) and members of a local community (Lindegger et al., 2003). 
3.4 Sampling procedure 
The sample was made up of a total of 35 participants. Ultimately, only 33 participants' data 
was used in the analysis due to the fact that one tape was in-audible and therefore impossible 
to code and in the other case one participant kept on switching between Zulu and English 
during the interview. After careful consideration the latter was dropped from the data corpus 
to maintain consistency. Demographic variables included: gender, age, first language, 
religion, degree of study and motherhood (further described in chapter 4). Ideally, 
participants would have been stratified equally along these demographic variables but due to 
the practical constraints it was not possible to achieve random sampling. As an exploratory 
study the aim was not to have generalisable results, as indicated by the both the sample size 
and the non-random sampling employed, but rather to extrapolate the results. 
The sampling procedure employed in the study drew on a number of sampling techniques, 
primarily convenience sampling. The sample used in the study comprised of university 
students mainly from residences. The choice of students was largely influenced by the fact 
that students are an accessible sample. The researcher was also enrolled at the university, 
which facilitated negotiation of access onto site, especially given the time constraints 
(Silverman, 2000). Although this may have its disadvantages, researcher pleasing or social 
desirability for example, the benefits were estimated to outweigh the risks. It could be argued 
that it also provided the researcher a unique and privileged position of understanding of 
possible 'in-group' dynamics. In addition, steps were taken by the researcher to minimise 
potential disadvantages and conduct research ethically (discussed in section 3.8). Research in 
the field has investigated various groups of people, with a few focusing on student 
experiences. As an exploratory study the current study was also interested in students as a 
sub-group of the population. Furthermore the researcher knew that university students have 
been targeted for recruitment programs for HIV vaccine trials in Gauteng, South Africa (see 
section 5.4) and therefore the results of the current study could inform a subset of the 
population which will be targeted for HIV preventive vaccine trials. 
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The exploratory nature of the research project also enabled flexibility in the data collection. 
After initial analysis of the first few interviews it appeared that mothers and non-mothers 
within the student population may have different experiences with vaccination. Purposive 
snowball sampling was used to identify cases of interest, namely mothers (Patton, 1990). 
These participants told their friends about the research and so data collection snowballed. 
Following consultation with either residence administrators or assistants, four university 
residences were identified for data collection. Two of these were undergraduate residences 
and the latter postgraduate residences. From the undergraduate residences one was a female 
residence, another a male residence while the postgraduate residences were both co-ed. 
Residence administrators or assistants advertised the study in the four residences through 
house meetings and by word of mouth. Prospective participants would leave their names and 
contact details with their resident assistant, who would pass on the information to the 
researcher. The researcher would then independently contact the prospective participants and 
arrange a suitable time to conduct interviews, which were audiotaped to allow for subsequent 
referral to rich text quotes from participants. 
While the researcher thought that data collection would go very quickly, given the setting, in 
practice data collection proved to be lengthy. This can be partially attributed to the sensitive 
and confidential nature of ADDS research (Melton, Levine, Koocher, Rosenthal & Thompson, 
1988). Despite attempts to reassure students that the research was a study of perceptions and 
attitudes to general vaccination and not an 'AIDS' study and that their identity would remain 
anonymous, many were dissuaded and chose not to participate. However, from those who 
volunteered, no resistance or apathy was noted. 
3.5 Measures 
3.5.1 Interview procedure 
Interviews were conducted in a pre-arranged room designated by the respective residences, in 
a conducive environment for taping. At the start of each interview the aims of the study were 
described to all participants, who were then given an information sheet on the study (see 
Appendix A). An opportunity for participants to ask any questions or clarify any concerns 
was then afforded to all participants. All participants were required to give written informed 
consent for participation, and to audio tape the interview (Appendix B). Participants were 
informed beforehand that the interviews were confidential and anonymous and that if they 
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were not comfortable with audio taping detailed written notes would be taken instead. Once 
informed consent had been obtained, all participants initially filled in a form with their 
demographic details before proceeding with the interview. In the interview participants were 
asked open- ended questions with occasional close-ended questions, each interview spanning 
approximately 30 to 45 minutes. After that interview participants were again given an 
opportunity to ask questions. All participants were then thanked for their participation and 
given a refreshment as a token of appreciation for their volunteering. 
On occasion environmental disturbances such as lawn mowers, or students playing their 
radios loud, were encountered. In such incidences interviewing proceeded if the noise was 
tolerable. Otherwise, interviews were temporarily suspended and reconvened once conducive 
for taping again. Notably, this was very rare and only occurred once or twice. 
3.5.2 Interview schedule 
Face to face semi-structured interviews were conducted in English by the researcher. The 
interview schedule consisted of two parts. The first part elicited demographic information. 
The researcher was particularly interested in whether or not demographics, particularly 
gender and between mothers and non-mothers, were associated with perceptions of 
vaccination. The second part of the interview schedule explored participants' understandings 
and experiences of vaccination, predominately using open- ended questions. The open-ended 
nature of questioning fitted in with the exploratory nature of the study. That is, while the 
interview schedule provided a useful structure to ensure consistency between interviews, it 
also allowed for flexibility to probe further when participants brought up interesting or new 
ideas (see Appendix C). 
As already mentioned in section 3.3 the current study is part of a series of studies conducted 
by Lindegger et al. (2003) and da Silva (2003). These studies were conducted in two 
communities in kwa Zulu -Natal. The same interview schedule has been used across all three 
studies. The interview schedule was deliberately designed to elicit both diversity of opinion 
and details of specific viewpoints. Unlike most research in the field, which uses Likert type 
scales and other forms of closed ended questions the measure instrument in this study utilised 
open ended questions to sample diversity of opinion. Originally formulated by Lindegger et 
al. (2003) a subsequent study (da Silva et al., 2003) modified the questionnaire to match the 
community from which the participants were drawn. Also, in the current study the interview 
schedule was slightly modified and tailored to omit redundancy, and additional questions 
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according to the researcher's research interest were included. Questions were also added to 
explore in more detail students' perceptions of HIV preventive vaccine trials. Additional 
items included: 
> Have you heard about an HIV vaccine? 
> Who do you think should be vaccinated? 
> What do you think about the vaccine? Do you think it is a good /bad thing? 
3.6 Data analysis 
Data analysis began after an initial set of interviews, reflecting the ongoing nature of 
qualitative data analysis that takes place throughout the research project (Mauthner & 
Doucet, 1998, in Gambu, 2000). To maximise consistency between samples in the larger 
study and allow future comparison between studies, the original coding schedule was 
maintained and the same coder was used. However, ongoing data analysis revealed that 
certain codes needed further refinement and in some incidences new codes were developed. 
See Appendix D for the coding schedule used in this study. 
Traditionally, content analysis has been the most favoured method used by quantitative 
researchers to analyse text of different forms (Silverman, 2000). Historically, this entailed 
imposing predetermined categories onto the data and counting the number of instances a 
category came up (Neuman, 2000). In the current study content analysis was applied to the 
data and a level of interpretation was applied, as coding was often latent rather than manifest. 
Coding also entailed extracting similar and common meanings. Content analysis was ideal for 
the current study because it straddled the gap between qualitative and quantitative 
components of the study, thereby suggesting that the relationship between these two is not 
necessarily mutually exclusive but perhaps on a continuum. The use of counts and Chi-square 
helped to describe popular views and explore possible significant associations between 
selected codes and demographic variables such as motherhood and gender. 
3.6.1 Coding system 
Using content analysis, a coding system was developed in the original study. The coding 
schedule was designed to pick up themes as they occurred naturally in the data corpus. After 
an initial generation of an exhaustive coding scheme, these were abstracted and reorganised 
into a hierarchal coding schedule. Unlike other contemporary variations of content analysis, 
which advocate that categories should be mutually exclusive and exhaustive (ibid), the codes 
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in current study were not expected to be mutually exclusive. That is, the coding schedule was 
designed to allow any extract to be coded into more than one category where necessary 
(Weber, 1985). 
The same coder from the larger study was employed in the current study. This coder was 
used for two primary reasons. Firstly, this facilitated a level of consistency across the three 
studies. Secondly, having coded all the previous data the coder had gained a level of 
familiarity with the coding, ensuring reliability across samples. All 33 interviews were coded 
and the findings were recorded onto a coding form (see appendix E). The count where each 
code occurred was also recorded in each interview to allow the researcher to subsequently 
return to original text. In addition, rich quotes were also selected and recorded on the same 
coding schedule to allow the researcher to illustrate themes. 
3.6.2 Analysis of codes by demographic variables 
Only one recording per code was made. Thus even though each code may have appeared 
more than once each code was only used once per interview. Each code was converted into a 
count for Chi-square analysis. Chi-square analysis was used to investigate the nature of 
relationship between certain demographics and codes. These comparisons were kept to a 
minimum to limit the family-wise error rate. Of the total 189 codes 64 were selected for Chi-
square analysis -18 pertained to understandings of vaccination in general, 15 to experiences 
with vaccination and 31 to HIV vaccine trials. Regarding understandings of vaccination the 
selected codes included knowledge of the purpose of vaccination, vaccine mechanism, 
vaccine target and specific diseases for which there are vaccines. Selected codes on 
experiences with vaccination referred to side effects and personal experiences. With regards 
to knowledge, expectations of vaccine trials and willingness to participate, selected codes 
related to the following: general knowledge and awareness of vaccination; willingness to 
participate in a hypothetical vaccine trial; perceived incentives; and barriers to vaccination. 
Thus, if alpha is set at .05, all things being equal, then it would be expected that of the 64 
selected codes three significant results would be expected by chance alone. Given the fact 
that the sample was only made up of 33 cases, which were non-randomly selected this would 
have the impact of reducing power and limiting the statistical generalisibility of the results to 
other samples or populations. Therefore the results have to be considered very carefully as 
the chance of committing a Type II error, that is the chance of not finding a significant result 
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that may actually exist, can be considered quite high in the current study. Nonetheless, the 
aim was not to produce statistically generalisable results but rather to identify possible trends 
between certain responses and demographics (e.g. gender), which could be explored in future 
research. 
3.6.3 Reliability and validity 
No formal reliability and validity measures were calculated in the current study. However, 
attempts were made to enhance accuracy and consistency. The use of the same coder across 
all three samples facilitated this process. The researcher also felt it would be more 
constructive if the coding process were also learnt. Therefore the researcher coded a number 
of transcripts to aid correct interpretations of the data. While the researcher was familiar with 
all the interviews, five interviews were randomly selected for thorough implementation of the 
coding schedule. 
This exploratory study did not aim to generate generalisable results but rather to extrapolate 
results, which was further enabled by the purposive sampling employed in the study. That is, 
while the findings in the current study may not be generalised to the entire population of 
prospective trial participants, results may apply to a subset of the population, namely 
students. With purposive sampling, information rich cases are selected for in-depth study 
(Patton, 1990). That is, while only 33 were sampled, these were considered rich with 
information. In addition, the researcher had reached saturation and no new themes were 
emerging. Thus the focus was on depth rather than quantity. 
3.7 Ethical considerations 
Careful consideration to ethical requirements was given in the present study. As mentioned in 
Chapter 2, the need for the rigorous application of ethics in South African research is 
paramount. Not only does it serve as "good practice" but also to foster an atmosphere of 
mutual respect and cultural sensitivity consistent with the South African constitution. The 
researcher was also a student at the university, which allowed the researcher to capitalise on 
an 'in-group' dynamic, thereby facilitating access on site. This could have raised a concern 
regarding the dual role of the researcher (as a student on the one hand and a researcher on the 
other). Deliberate attempts were made to ensure informed consent, free from coercion. Each 
participant was given an information sheet, briefly outlining the study (as mentioned in 
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section 3.5.1). This is attached as Appendix 1. All participants were also required to give 
written informed consent to the interview. This is attached as Appendix 2. Consent was also 
obtained for audio-taping (also see Appendix 2), with the option of taking intensive notes if 
the participants felt that the taping was intrusive. In addition, to ensure confidentiality all 
interviews were conducted in a closed room. Furthermore, all participants were assigned 
codes to ensure anonymity. The researcher also had a system, which allowed for 'cracking 
the code' in case further information from participants was further required. This was clearly 
explained to all participants. 
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Chapter 4: RESULTS 
4.1 Introduction 
In the current chapter the results of the study are presented. The chapter begins with a 
demographic description of the sample. This is followed by a description of the results of 
participants' knowledge and experiences with vaccination. In the final section, participants' 
perceptions and expectations of HIV vaccine trials are presented. 
4.2 Demographic profile of participants 
Table 1 (overleaf) gives a summary of the demographic profile of the participants. Almost 
half of the participants (45%) were male while the remainder (55%) were female. Four age 
categories were present in the sample. The biggest age category was the 21-30 age group with 
n = 20 people. Other age categories consisted of 14- 20 (n = 7), 31-40 (n =4), and 41-50 (n = 
2), respectively. Participants came from various first language backgrounds. The five most 
common languages, of the eleven official South African languages, were English (n = 9), 
Zulu (n = 9), Sepedi (n = 4), Xhosa (n = 3), and Sesotho (n = 2), respectively. Thus, while 
only close to a third (27%) of the participants were English first language speakers, the 
remaining 73% were bilingual - with English being the primary medium of instruction and 
writing in the university. More than five religious groups were represented in the sample, 
while 27% of the sample stated that they had no religious affiliation. All participants were 
spread across three faculties. The largest grouping (n = 15) came from the Arts / Social 
Science faculty while other participants came from the Faculties of Science (n = 10) and 
Commerce (n = 8) respectively. In addition, from the total of eighteen females, six were 






















































































Table 4.1: Demographic profile of participants 
4.3 Knowledge, perceptions and barriers to vaccination 
The results presented in this section pertain to objective 1 of the study, that is, to assess 
students' knowledge and perceptions of vaccination. Specific questions were asked 
concerning the purpose of vaccination, vaccine mechanism, vaccine-preventable diseases, 
perceptions of health-care workers, perceptions of vaccine target populations, preferred 
sources of information, safety, side-effects and barriers to vaccination, alternatives to 
vaccination, vaccination and human rights and educational needs. 
4.3.1 Knowledge of the purpose and mechanisms of vaccination 
All participants displayed some level of knowledge about vaccines with no one participant 
stating that s/he did not know anything about vaccination. The vast majority of the 
participants, that is 97% (n = 32), cited that the purpose of vaccination was to promote health 
or prevent illness, while the remaining 3% (n = 1) said vaccines cure disease. A fairly high 
number of participants, i.e. 64% (n = 21), also felt that vaccines were medically helpful. Less 
common responses to the purpose of vaccination cited by 18% (n = 6) included the 
perceptions that while vaccines protect against disease they are not necessarily 'fool proof. 
In the words of one mother: 
"...Some children do die from measles whereas they had the injection to protect them from 
catching measles. So in that sense I would say even those things are not 100% perfect. But I 
still take my children, just as a precaution. They might get it (disease), they might not. " 
One mother felt that vaccines guarantee immunity and expressed disillusionment in vaccines 
when they did not eliminate her child's susceptibility to disease. She stated: 
"Yes she got vaccinated for measles and she got it twice already. And she had all her shots in 
time. So I lost faith in the thing. " 
Of those who felt that vaccines promote health or prevent illness 9% (n = 3) also said 
vaccines cure disease or treat illness. 
With regards to the mechanisms by which vaccines work, two participants were unsure of the 
mechanism by which vaccines work while 67% (n = 22) of the participants referred to the 
mobilization of the immune system by using terms like pathogens, T- cells, anti-bodies and 
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immunity. One participant had this to say in response to the question "What does vaccination 
do?" 
"Well I think that it tries to boost immunity by producing anti-bodies that boost your 
immunity to certain diseases. " 
A significant minority of participants, that is 27% (n = 9), used metaphors of strength and 
power to explain how vaccines work, stating that vaccines make one strong and able to fight 
diseases. One participant reported the following when asked how vaccination protects against 
disease: 
"Um, I know in the body you have antibodies that prevent diseases. I think that it helps to 
fieht off diseases... I think it just helps the antibodies, to give them more fighting power 
against the bacteria of the disease. " 
4.3.2 Knowledge of diseases that are vaccine preventable 
Regarding knowledge of diseases that are vaccine preventable most participants, that is 91% 
(n = 30), stated common vaccine-preventable diseases. Of these participants who named 
common vaccine-preventable diseases the majority (n = 19) mentioned more than one 
vaccine-preventable disease. Common vaccine-preventable diseases included measles, 
chicken pox, smallpox, polio, tuberculosis, BCG and influenza. However, from this same 
group 57% (n = 17) also mentioned other common diseases that were not in fact vaccine-
preventable, the most prominent being malaria. Thus, while the majority of participants 
(91%) correctly mentioned at least two vaccine-preventable diseases, a significant number of 
these participants (57%) also incorrectly mentioned other diseases. In response to whether 
there were any diseases that vaccines do not prevent against 70 % of overall participants (n = 
23) mentioned HIV, although 3% (n = 1) cited HIV as a vaccine-preventable disease. 
Participants also alluded to the exclusive relationship between vaccines and disease 
(illustrated by the citations below). As one participant put it, people get vaccinated: 
"... To prevent the development of the disease that you want to be vaccinated from. " 
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Another had this to say: 
"Um, well I know that you get measles ones when you are a child to prevent from getting 
measles. And you get ones for polio... " 
4.3.3 Knowledge of health-care workers (HCWs) views on vaccination 
In response to questions about information received from HCWs 40% of participants (n = 13) 
claimed to be either to be unsure or to have never heard what HCWs say (see Table 4.2 
below). Similarly, 36% (n = 12) stated that HCWs do not explain about vaccination. One 
participant pleaded: 
"Maybe they could be more tolerant, cause you get old people who are just helpless ...they 
are disregarded and treated with disrespect and I just think that staff at the clinics, hospitals 
and all vaccination centres could be more friendly... " 
Another response to what HCWS explain about vaccination was as follows: 
"No, they have never as far as I know about vaccination. " 
Only 9% (n = 3) of overall participants stated that they believed what HCWs say. Of these, 2 
participants felt that what HCWs had to say was helpful, another 2 stated that HCWs said 
vaccination was a way of taking proper care of children while one participant stated that 
HCWs said that vaccines prevent disease. With the exception of the latter and former 
responses no attempts were made to explain what it was that HCWs said about vaccination. 
Participants perceptions of HCW's views of vaccination 
Unsure, or never heard 
HCWs do not explain 
Believe what HCWs say 
HCWs say vaccination is way of taking proper care of children 
What HCWs say is helpful 
HCWs say vaccines prevent disease 

















Table 4.2: Percentage of participants reporting specific views of health-care workers 
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4.3.4 Perceptions of vaccine target populations 
Seventy percent of participants (n = 23) believed the target population of vaccination to 
extend to all people of all ages (refer to Table 4.3 below). One participant responded in the 
following way when asked whom vaccination was for: 
"Everyone! It 'sjust that grown ups don't really take or think of it much. It seems like it 'sfor 
kids but its for everybody. " 
However, many expressed uncertainty about the specific population target. The majority of 
participants, that is 82% (n = 27), felt that healthy people should be targeted because they too 
"can get sick". As one participant put it: 
"...I don't think you can ever be like 100% healthy. Yah, so even healthy people should get 
vaccinated." 
Forty two percent of the entire sample (n = 14) felt that vaccination should be mainly for the 
sick. Forty percent of overall participants (n = 13) believed that vaccination should target 
both the healthy as well as the sick. Just over a third of all participants, that is 36% (n = 12), 
felt that children should be the main targets of vaccination, while 12% (n = 4) felt that 
vaccination should target both adults and children. Fifteen percent (n = 5) of the participants 
stated that vaccines should be mainly for people at risk. 
Target of vaccination 
All people of all ages 
Mainly healthy people 
Mainly the sick 
Both healthy and sick people 
Mainly children 
Mainly adults 
Both children and adults 
Mainly people at risk 





















Table 4.3: Percentage of participants mentioning specific vaccine target populations 
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4.3.5 Actual and preferred sources of information regarding vaccination 
With reference to sources of information about vaccination more than half of all participants, 
namely 58% (n = 19), reported clinics, hospitals and schools as their primary information 
resource (as illustrated in the table below). This also included posters and pamphlets therein. 
Twenty one percent of overall participants (n = 7) reported that they had received their 
information from the media while fifteen percent (n = 5) mentioned other sources like friends 
or neighbours. 
Reported actual sources of information 
Clinics, hospitals and schools 
Media 
Other sources, e.g. friend or neighbour 











Table 4.4: Percentage of participants reporting actual sources of information 
When asked about preferred sources of information different results were obtained (see Table 
4.5 below). Media channels were the most common response, cited by 40% (n = 13). Twenty 
one percent of the participants (n = 7) listed medical sources, such as HCWs, as their 
preference. Two participants stated that anyone with credibility and knowledge would be 
preferred while one participant mentioned friends and neighbours as their preferred choice. 
Reported preferred sources of information 
Media channels 
Medical sources such as HCWs 
Anyone with credibility and knowledge 
Other sources, e.g. friends and neighbours 













Table 4.5: Percentage of participants reporting ideal sources of information 
4.3.6 Reported barriers to vaccination 
As there is a degree of overlap between perceived safety and barriers to vaccination these are 
described simultaneously in the following section, as part of identifying perceived negative 
factors associated with vaccination (refer to Table 4.6 overleaf). 
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When asked to speculate on possible barriers to and difficulties with vaccination the most 
common response was lack of information, knowledge or education about vaccination 
reported by 70% (n = 23). A third of the sample, that is 36% (n = 12), believed that logistical 
difficulties such as cost and transport could account for people not getting vaccinated. A 
significant minority of overall participants, namely 27 % (n = 9), expressed concern about the 
physical or medical safety of vaccination as a barrier. Almost a fifth of all participants, that is 
24% (n = 8), mentioned cultural or religious barriers, although when asked to expound on 
these only a few examples (n = 2) were forthcoming. One respondent had this to say about 
what may stop some people from getting either themselves or their children immunised: 
"You see each person has a world view. Sometimes this is defined by culture. So someone 
may believe 'vaccine no ways'. 'Why should I have that in my body?' You also have these 
totalistic people who believe that 'God will provide for me'. 'I don't need a vaccine.' You see 
people don 7 understand that life is a bit of everything. You have a kind of totalistic 
viewpoint: 'I don't need that, God is my saviour. He will protect me.' Those are the beliefs 
that people have." 
Of the entire sample 18% (n = 6) expressed fears that vaccines may directly cause illness. 
Several participants, i.e. 6% (n = 2), listed intrapersonal factors. Examples include claims that 
some just don't care and laziness. One participant believed there to be no barriers to 
vaccination. 
Reported barriers to vaccination 
Lack of information (education) about vaccination 
Logistical difficulties (e.g. cost, transport etc.) 
Concerns about the physical or medical safety of vaccination 
Culture or religious barriers 
Fears that vaccines may directly cause illness 
Intrapersonal factors (such as laziness) 
No barriers to vaccination 



















Table 4.6: Percentage of respondents reporting barriers to vaccination 
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4.3.7 Perceived alternatives to vaccination 
Regarding alternatives to vaccination the majority of participants, that is 73% (n = 24), stated 
that alternatives do exist; 18% (n = 6) felt that there were not any, and 9% (n = 3) were 
uncertain. Health alternatives were the most commonly cited by 67% of the participants (n = 
22). These included adequate dietary, sanitary and exercise requirements. Only one 
participant explicitly mentioned cultural alternatives while no one mentioned religious 
alternatives, although both were stated as possible barriers to vaccination. Twenty four 
percent of the participants (n = 8) felt that alternatives were complementary to vaccination. 
Eighteen percent of the participants (n = 6) believed that alternatives were better. However, 
none of the participants stated that alternatives were necessarily worse or least preferred. 
Reported alternatives to vaccination 
Yes, alternatives exist 
Health alternatives (diet, sanitation, exercise) 
Cultural or traditional alternatives 
Religious alternatives 
No, alternatives do not exist 
Uncertain 

















Table 4.7: Percentage of respondents reporting alternatives to vaccination 
4.3.8 Vaccination and human rights 
In response to whether or not there should be a law forcing people to be vaccinated there was 
diversity of opinion among participants (refer to Table 4.8 on the following page). Less than 
half of all participants, i.e. 42% (n = 14), felt that vaccination should be enforceable by law. 
Of these 4 participants felt that the populations right to be protected from disease should take 
precedence over an individual's right to choose to vaccinate or not. Thirty six percent of 
participants (n = 12) believed that vaccination should be a choice, 7 of which further stated 
that individual human rights should be taken into account. A fair number of participants, 
namely 21% (n = 7), expressed uncertainty or ambivalence about whether or not there should 
be a law forcing people to get vaccinated. One participant voiced strong objections about this 
particular question, stating that it was a politically loaded question and unfair to ask in the 
first place. One participant had this to say: 
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"Because people are so diverse, some people say my culture does not allow this. My religion 
does not allow this. It should be a choice. But I believe people if they are told that these 
vaccines are helpful...I do believe you will go there willing. I don't believe there will be 
someone forcing you..." 
Perceptions on human rights regarding vaccination 
Vaccination should be enforceable by law 
Population's right to protection more important 
Vaccination should be optional 
Individual human rights more important 
Uncertain/ ambivalent 















Table 4.8: Percentage of respondents reporting human right opinions regarding 
vaccination 
4.3.9 Stated educational needs 
The vast majority of participants, that is 88% (n = 29), felt that they wanted to know more 
about vaccination (as illustrated in the table below). Of these 18 participants mentioned that 
they would like more input on how vaccines work, 12 mentioned that they would like more 
information about vaccination in general and 6 said that they would like more information on 
what vaccines were actually available. A small minority, namely 12% (n = 4), stated that they 
had no educational needs regarding vaccination. 
Educational needs 
Yes, I would like to know more 
Would like more input on how vaccines work 
Would like more general vaccination information 
Would like to know what vaccines are available 
No educational needs 















Table 4.9: Percentage of respondents reporting educational needs 
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4.4 Personal experiences and uses of vaccination 
The results presented in this section pertain to objective 2; that is to assess students' 
experiences of vaccination in general. In the following section personal experiences and uses 
of vaccination will be presented together as they appeared related. Most participants in the 
study, i.e. 88% (n = 29), reported that they had been vaccinated (see Table 4.10 overleaf). 
Three of these could give a clear account by describing their personal experience of 
vaccination. One Xhosa student had this to say: 
"Of course, I remember the experience. It was painful because they used a needle. And 
sometimes you used to get drops under the tongue, which was painful. And I remember at the 
clinic just cause they used to set one date for a certain age of babies. So, the whole 
community would come to that clinic and it just used to be packed. Children were crying and 
nurses were getting impatient. Sometimes it just used to be chaotic but you know you used to 
sit all day sometimes and wait for the queue, for your turn. Babies were crying and people 
pitched on the wrong day. And they would have to go back. Most of the people they came 
from the rural areas. So they travelled and it was a disadvantage and an inconvenience to 
them if they got the wrong date. But I was lucky, cause I was from around, in town. " 
Two reported that their experiences had been helpful. Eight participants claimed that their 
experiences had been negative and 12 reported they had experienced side effects such as: 
discomfort, sickness, and in one case temporary paralysis. Discomfort experienced as a result 
of vaccination included pain (especially from needles), swelling, fever and fatigue. In most 
cases participants who reported side-effects did not explicitly mention them as barriers but 
saw them as an integral part of vaccination. One mother put it like this: 
"Um, I took my baby when she was six weeks. I took her to the clinic. She got two injections 
in her thigh and I was told that the baby is going to get sick. She's going to get feverish. I 
must try and keep her cool, don't worry about bringing her to the clinic cause there is 
nothing we can do about it. " 
Similarly, one participant said the following about pain from the needle: 
"/ think you sort of expect it. So sometimes it's not at all that painful but some people seem to 
think that different people who actually deliver the vaccine actually ... deliver it differently. 
So some may make it sore, some will do it in such a way that you don 'tfeel much pain. " 
Another participant had this to say: 
"...I remember this one time I was in the vaccination room and it was my turn to get 
vaccinated and I just ran out of the room. And the nurse chased me and she got me back and 
I got vaccinated. It was horrifying. I hated it. I just never liked it. " 
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Of those who reported having been vaccinated before only 11 had also been vaccinated since 
childhood while 10 reported that they had not been vaccinated since childhood. A few 
participants, i.e. 6% (n = 2), stated that they had not been vaccinated at all. Six percent of 
participants (n = 2) also had no or insufficient knowledge about their own vaccination. Of the 
six mothers present in the study all (n = 6) stated that they had their children vaccinated as 
they felt it was obligatory. One mother had the following to say about vaccination: 
"It's a thing that's done that when a child is young, like six weeks old. They get vaccinated 
for polio and such things. There isn 't any specific reason except that it's something that has 
to be done." 
More than half of overall participants, i.e. 61% (n = 20), indicated that their friends and 
family vaccinate, and 18% (n = 6) stated that their friends and family don't vaccinate. When 
asked why friends did not go for vaccination one participant said the following: 
"No! They are all grown up now. They went when they were children. But their children, like 
my little nephews and nieces do ...you see I'm not sure what happens with a vaccine. I'm not 
sure whether it is long term or maybe just a couple of years that it works or what. " 
Experiences and uses of vaccination 
Have been vaccinated 
Clear knowledge of personal vaccination history 
Vaccination was personally helpful 
Vaccination had negative consequences 
Experienced side-effects (e.g. discomfort or sickness) 
Have been vaccinated since childhood 
Have not vaccinated since childhood 
Have not been vaccinated 
Unclear knowledge / no knowledge of own vaccination history 
Vaccinates children (answered by mothers in the study) 
Vaccinates children to protect and prevent disease transmission 
Vaccinates children for other reasons 





























Table 4.10: Percentage of participants mentioning specific experiences and uses of 
vaccination 
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4.5 Perceptions of HIV vaccines, and vaccine trials: perceived barriers and 
willingness to participate (WTP) 
The following section presents results that pertain to objective 3, that is to assess knowledge 
and expectations toward HTV vaccination and participation in a hypothetical HIV vaccine 
trial. 
4.5.1 Knowledge and expectations of potential HTV vaccines 
Fifty two percent of overall participants (n = 17) stated that they had never heard of the 
possibility of an HIV vaccine while 36% (n = 12) said they heard of a possible HIV vaccine 
(see Table 4.11 on the next page). Of these 4 participants mentioned antiretroviral drugs such 
as AZT as an "existing HIV vaccine". This may be partially attributed to the publicity given 
to antiretroviral drugs by AIDS activists, especially to reduce vertical transmission of HTV, in 
the media at the time when interviews were being conducted. One participant had this say in 
response to whether or not they had heard of a possible HIV vaccine: 
"I've heard about it. But I'm really not sure whether it prevents getting infected or helps 
people who are already infected. But I've just heard about these vaccine trials all over the 
news. I don't know whether it has started or whether it is going to start. They are going to 
take a sample of people to see if it works. So I'm not quite clear. " 
Another had the following to say: 
"HIV vaccine? No! Is the antiretroviral a vaccine? ... No, no! I've never heard of one. " 
Yet another participant has this to say: 
"Well I think, I don't know if such a thing would actually occur. But if it actually did help it 
would probably work like the immune boosters do but not like eliminate the virus from the 
body. But I don't know. Miracles have happened." 
Regardless of whether or not participants had heard of a prospective HIV vaccine or not 
participants were then asked whether they thought a hypothetical vaccine would be for 
prevention or treatment and whom would such a vaccine target. As illustrated in the table 
below there were varied reactions to the prospect of HIV vaccines. Forty five percent of 
participants (n = 15) believed that a possible HIV vaccine would be preventive in nature, and 
thirty nine percent of all participants (n = 13) believed that such a vaccine would be mainly 
for uninfected people. Although none of the participants (0%) stated that the vaccine would 
66 
be a treatment, a significant number of overall participants, i.e. 24% (n = 8), mentioned that it 
would be mainly for HIV positive people. Forty five percent of participants (n = 15) felt that 
it should be for everyone. Twelve percent of the participants (n = 4) were of the opinion that 
it was mainly for people at risk of contracting HIV. 
Purpose of potential HIV vaccines 
Never heard of possible HIV vaccine 
Have heard of possible HIV vaccine 
Prevention 
Mainly HIV negative people (uninfected people) 
Treatment 
Mainly HIV positive people (infected people) 
All people, everyone 
Mainly people at risk 





















Table 4.11: Percentage of respondents reporting perceived purposes and target of 
HIV vaccines 
4.5.2 Stated willingness to participate (WTP) in potential HIV vaccine trials 
In general, people expressed varied feelings about participation in a possible HTV vaccine 
trial (see Table 4.12 overleaf). Almost a third of overall participants, that is 33% (n = 11), 
reported that they would not be willing to participate in a preventive HIV vaccine trial. Thirty 
percent of all participants (n = 10) stated willingness to participate, all of whom stated that 
they would require more information about the vaccine trial. Of those willing to participate, 9 
participants stated they would be willing to participate on condition that they were guaranteed 
that no risks would be incurred from their participation. One participant stated willingness to 
participate would be subject to family members being cared for in the event of a 'mishap'. 
Others stipulated the following conditions: 
"If I would be assured that there wouldn 't be permanent side effects I think I would give it a 
try as long as I don't die in the procedure or because of some of the complications. If it is 
shown to have no permanent side-effects." 
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"It would have to be a fully controlled and monitored procedure, a procedure in which urn, 
everything must be explicit to the person involved. It must be a completely genuine thing 
where you are made aware of the risks. So there must be complete exposure of what will 
happen because we are dealing with a persons life. " 
"People are definitely going to want to know if they are going to die or not, the risks - what's 
going to happen to you. They must be able to explain what is going to happen in your body -
the process. They must be able to hypothesise... " 
"Well it depends on whether I have it or not. If I don 7 have it I might be afraid that they 
might inject me with the virus. It I do it might get my hopes up thinking it's going to work and 
I might be too disappointed, in the event it doesn 7 work." 
Another participant said that willingness to participate would be purely for financial benefit. 
Fifteen percent of the entire sample (n = 5) indicated that they were unsure whether they 
would participate or not. 
Stated willingness to participate 
Not willing to participate 
Willing to participate 
Require more information 
Need guarantee that no significant risks will be incurred 
Need assurance that family will be taken care of 
Require financial benefit 
Unsure 



















Table 4.12: Percentage of respondents reporting to willingness to participate 
4.5.3 Personal and perceived incentives for trial participation 
Personal incentives and perceived incentives for other prospective participants differed, thus 
they are described separately (see Table 4.13 on the next page). With regards to personal 
incentives altruism was the most popular response (39%) overall. As one participant put it: 
"I think I would feel very happy because there is something that is happening - that is taking 
people I know. It's not something like a myth anymore. Because in the past they said AIDS is 
a myth, it does not exist - depending where they come from. I would be honoured. " 
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Fifteen percent of the sample stated compensation - in the event that something should go 
wrong - as an incentive for their participation. In the words of one participant: 
"A million bucks and a BMW and maybe a house. Seriously, what would I want? Uh, mostly 
what I can say is compensation for everything that could possibly happen... " 
Other incentives included recognition, medical benefits (e.g. medical aid, access to treatment 
during the trial and access to free vaccine once available) and opportunity to reduce personal 
risk to HIV infection, respectively. Regarding recognition one participant had the following 
to say: 
"What I would want! Something on my C. V. to say that I participated in such a thing. Yah, 





Medical benefits (e.g. access to treatment) 
Opportunity to reduce personal risk of infection 















Table 4.13: Percentage of participants reporting perceived personal incentives 
When asked to speculate on perceived incentives for others material benefit was stated as the 
most popular incentive while no mention of altruistic intentions was made (as illustrated by 
Table 4.14 on the following page). Opportunity to reduce risk of infection was the second 
most popular response. Examples included the perception that participants would be 
completely protected from HIV infection and that some might see the vaccine as a cure. One 
participant expressed the following hopes for a prospective HIV vaccine: 
"... you get healed if you are infected. And if you were not infected you get something like a 
protective factor." 
The remaining participants reported recognition, medical benefits and counselling as 




Opportunity to reduce risk of infection 
Recognition/ Acknowledgement 
Medical benefits (e.g. guarantee of medical care) 
Counselling 
Altruism 

















Table 4.14: Percentage of participants mentioning perceived incentives for others 
4.5.4 Perceived barriers and concerns about trial participation 
As there was a degree of overlap between concerns about potential HIV vaccines and 
perceived barriers to trial participation these are described together. The most common 
perceived barrier to trial participation cited by 61% of participants (n = 20) was significant 
physical risk (see Table 4.15). Examples include: fear of contracting HIV through the vaccine 
trial, other illness, side effects, as well as fear of the unknown. Two participants raised the 
following issues: 
"Like I was saying it has never been tried on anyone else and being the first one it is quite 
scary, cause they don't know what will happen. What is it going to do to you? " 
'...there may be something negative that happens to me after that vaccine trial. Maybe I'll get 
some illness and I don't even know what that would be. And being sure that I'll be treated 
and maybe know who to contact should something happen tome..." 
Concern about psychosocial risk was the second most popular response. Commonly cited 
examples included fear of stigmatisation and increased sexual behaviour as a result of a 
vaccine trial. In this regard here are various quotations from participants: 
" When people hear about vaccines it may have an impact on their behaviour. A person will 
just do as they wish with their body and sleep around, knowing that there are vaccines 
coming." 
"I think people would become irresponsible because there is still other things that it could 
lead to. For example, pregnancy, it's not just HIV. So you could get a whole lot of unwanted 
pregnancies." 
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"... at the moment people are afraid to stand up and say that they are HIV positive. And if 
they go out telling others they are going for these vaccines, what if they do not help? I think 
that is where most of the fear will come from. Because people are shy - not so much that they 
are shy, they always worry about other people - what are they going to say ..." 
"One fear could be stigmatisation. Some people have weird beliefs. Some believe that now 
that they have got the "AIDS vaccine " they have got the AIDS virus or something...' 
Another perceived barrier was concern about affordability of the vaccine. Two different 
participants had the following to say about a possible vaccine: 
" Expensive, it would be expensive... " 
"...It might work to the advantage of rich people ... and the poor people might not have 
access to it..." 
Questionable efficacy of the vaccine was another perceived barrier to trial participation, as a 
third of participants, that is 30% (n = 10), feared that the vaccine might not work. In the 
words of one participant: 
"Oh, will it work? Because there has been so much hype about there not being a cure for 
AIDS... It could be hard ...to be convinced that it might just work. " 
Twenty four percent of participants (n = 8) were concerned that participants may become 
dependent on the vaccine. Twenty percent of the participants (n = 7) expressed other 
concerns. These included the possible danger of reused needles due to poor administration 
and shortage of services in rural areas. Others even claimed that HCWs deliberately injected 
people with HIV. As one participant said: 
"Even doctors now a days go around injecting people with the virus. So people don't trust 
anybody who comes close to them with needles. So that is the major problem. Most people 
would not consent to such a thing because they are thinking that there is catch. " 
Some articulated that the vaccine may be perceived as a political ploy derived from a white 
ideology. In the words of one participant: 
71 
"We have a very bad political situation in this continent and this country specifically. I think 
political history itself will drive away a lot of people from that vaccine in the same way as 
news about AIDS, you know turned a lot of people deaf really when it was first being 
announced on radios and so on, because people always thought it's these white people again 
they want to control our reproduction. And now it's worse because they 've also heard about 
the vaccine that could be said to have caused the disease. So people would approach it with 
serious caution. I don't think that they would really outright refuse to immunisation. But I 
think it will be a very slow process. " 
Perceived barriers and concerns about trial participation 
Significant physical risk (e.g. fear of contracting HTV) 
Psychosocial risk (e.g. stigmatisation) 
Affordability 
Questionable efficacy of vaccine (e.g. vaccine might not work) 
Concern about dependence on vaccine 


















Table 4.15: Percentage of participants reporting perceived barriers to WTP, and 
concerns 
4.6 Demographic associations with knowledge and experiences of vaccination 
The results based on research objective 4, which is to explore if particular knowledge and 
experiences are associated with demographics such as motherhood and gender, are presented 
below. 
Knowledge of vaccination (purpose, mechanism, and vaccine target) was not associated with 
gender or with motherhood. Regarding knowledge of vaccine-preventable diseases mothers 
were significantly less likely than non-mothers (p = . 045) to be aware that HTV is a disease 
for which there is currently no available vaccine (Chi-square value: 4.018, N = 18, df = 1). 
No significant differences were found between experiences of vaccination (uptake of 
vaccination and side effects experienced) and gender or motherhood. 
With regards to knowledge and expectations of HIV vaccine trials, several associations were 
found with gender and motherhood. The results revealed an association between familiarity 
with a possible HIV vaccine and motherhood but not with gender. That is, significantly more 
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mothers than non-mothers (p =. 034) said they had heard of a possible HIV vaccine (Chi-
square: 4.5, N =18, df = 1). Regarding WTP in potential HIV vaccine trials, results further 
revealed an association with motherhood. More specifically, significantly less mothers man 
non-mothers (p =. 034) expressed willingness to participate in HIV vaccine trials. In fact 
none of the mothers (0%) said they were willing to participate in HIV vaccine trials (Chi-
square: 4.5, N =18, df = 1). A significant association was also found between personal 
incentives for trial participation and motherhood, with significantly less mothers than non-
mothers (p =. 017) who stated altruism as an incentive for trial participation (Chi- square: 
5.527, N =18, df = 1). Finally, an association between perceived barriers to participation in 
HIV vaccine trials and gender was found. Specifically, females were significantly less likely 
than males (p =. 022) to be concerned about the psychosocial risks, such as increased 
reckless sexual activity and stigmatisation (Chi- square: 5.241, N =33, df = 1). 
4.7 Summary of results 
The vast majority of participants (97%) cited that the purpose of vaccination was to promote 
health or prevent illness, and 64% also said vaccines were medically helpful. The majority of 
the participants (67%) had an understanding of vaccination mechanism, stating that vaccines 
mobilise the immune system. The vast majority of participants (91%) were able to state 
common vaccine- preventable diseases, with 63% of these able to mention more than one. 
However, 57% also incorrectly mentioned other diseases that are not in fact vaccine 
preventable. A significant majority (over 70%) were unsure, had never heard what HCWs 
say, or said HCWs don't explain, about vaccination. The most preferred source of 
information was the media (40%) followed by health-care workers (21%). Perceived barrier 
to vaccination most commonly stated (70%) was lack of information, knowledge or education 
followed by concern about the safety of vaccination. Seventy three percent of the sample 
perceived alternatives to vaccination, mainly health alternatives (67%). A significant majority 
of participants (88%) had been vaccinated as children. Thirty six percent of the participants 
reported side effects. However, only 9% had clear knowledge of their personal vaccination 
history. Thirty three percent of the participants reported that they had been vaccinated as 
adults. All of the mothers in the study (n = 6) reported that they had vaccinated their children 
for various reasons. 
Most participants (70%) correctly stated that HIV was a dangerous disease for which there is 
currently no vaccine available. A majority of participants (52%) also reported that they had 
73 
never heard of possible HIV vaccines and 45% of the participants speculated that a 
prospective HIV vaccine would be preventive in nature. Thirty percent of the participants 
stated willingness to participate in hypothetical trials while 33% said they were not willing to 
participate. In terms of personal incentives for WTP, 39% reported altruism however no 
person described this as an incentive for others. Perceived barriers to WTP most commonly 
reported (61%) were significant physical risks followed by psychosocial risk sin n of trial 
participation (48%), especially regarding fear of stigmatisation and increased sexual 
disinhibitions. 
Knowledge, perceptions of vaccination in general and experiences, were generally not 
associated with demographics of gender and motherhood. However, mothers were 
significantly less likely than non- mothers (p =. 045) to be aware that HIV has no vaccine. 
Mothers were significantly more likely to say that they had heard of a possible HIV vaccine 
than non-mothers (p =. 034). Mothers were significantly less likely than non-mothers to 
express WTP (p =. 034). Mothers were significantly less likely than non-mothers to identify 
altruism as a personal incentive for trial participation (p =. 017). Significantly more males 
than females were concerned with psychosocial risks (p =. 022) of HIV vaccine trials. 
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Chapter 5: DISCUSSION 
5.1 Introduction 
As part of the national preparation for HIV safety trials in South Africa, the key objectives of 
the study were: i) to assess students ' understandings of vaccination: knowledge and 
perceptions of vaccination in general, including perceived barriers, ii) to assess students' 
experiences of vaccination, generally, iii) to assess students' knowledge and expectations of 
HIV vaccination and participation in a hypothetical vaccine trial, iv) to explore if particular 
knowledge and experiences were associated with demographics such as motherhood and 
gender. The chapter begins with a summary of the main results followed by a discussion of 
the results in terms of the four key objectives of the study. Finally, limitations of the study 
and implications for future research and preventive HIV vaccine trials are discussed. 
5.2 Central findings 
The following section presents a sequential discussion of the results grouped according to the 
four primary objectives. Other findings related to vaccination in general have also been 
integrated. Discussion of each objective comprises of comparisons of results with previous 
empirical studies, including ones not discussed in the literature review. 
5.2.1 Understandings of vaccination: Knowledge, perceptions and barriers to 
vaccination 
Knowledge of purpose and mechanism of vaccination 
Results in the present study revealed a sound general knowledge of vaccination purpose. The 
vast majority (97%) knew the general purpose of vaccination, stating that it is to promote 
health or prevent illness. Similar results were reported in China with 98.4% of participants 
(Zhang, et al., 1999), Ethiopia with 91.7% of participants (Gedlu & Tesemma, 1997) and 
Cape Town with 92% of participants (Van Staden et al., 1995) all stating that vaccines are for 
prevention. In general, empirical studies indicate that the understanding of the preventive 
notion of vaccination is common in different parts of the world (Kiwanuku et al., 2000; 
McCormick, Bartholomew, Lewis, Brown & Hanson, 1997; McGrath, Mafigiri et al., 2001; 
Tarrant & Gregory, 2001). In first world countries such as the US (McCormick et al., 1997), 
Canada (Tarrant & Gregory, 2001) and European countries (Angelillo et al., 1999), the 
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understanding of vaccination as preventive is common. In the developing world empirical 
studies conducted in many different countries (Gedlu & Tesemma, 1997; Kiwanuku et al., 
2000; McGrath, George, et al., 2001; McGrath, Mafigiri, et al., 2001; Van Staden et al., 
1995) indicate that understanding of the preventive notion of vaccination is also widespread 
although counter claims have been made in some countries. 
Specifically, in a study conducted in Nigeria, which sampled 200 mothers, the majority of 
participants (56%) did not believe that vaccination is preventive, with those of lower socio-
economic status and education favouring more supernatural explanations (Odebiyi & Ekong, 
1982). Of these the majority believed that vaccination is not preventive because they claimed 
that some of their children who had been immunised still contracted measles in later years. In 
contrast, in the current study a small minority of participants (18%) attributed this (children 
subsequently contracting diseases for which they were vaccinated against) to the fact that 
while vaccines protect against disease they are not 100% effective (or 'fool proof). This is 
consistent with the fact that no vaccine is 100% effective as the efficacy of most vaccines 
ranges from 85% - 90% (Pless, n.d.). Results from this study are supported by other study's' 
findings, which revealed a common understanding of the purpose of vaccination. 
When they were prompted about educational needs, many participants (55%) in the present 
study stated that they would like more input on how vaccines work. However, the majority 
(85%) offered plausible explanations as to how vaccines work when they were asked directly 
about vaccine mechanisms. A popular form of explanation applied by participants used 
metaphors of strength and power to explicate the action of anti-bodies in prevention. One 
participant had the following to say about vaccine mechanism: ".. .So I think it just helps the 
anti-bodies, to give them more fighting power against the bacteria of the disease." This can 
be likened with the use of military language to describe disease (including AIDS), which is 
familiar (Sontag, 1989 in McGrath, Mafigiri, et al., 2001). McGrath, Mafigiri, et al. (2001) 
found that antibodies were described as soldiers whose job it is to defend the body by putting 
out an alert to attack a specific enemy. Yet another view expressed by Odebiyi and Ekong 
(1982) posited that in Nigeria and in most developing countries the germ theory as a cause of 
disease had not yet been widely accepted. However, the findings of the current study and 
other more recent studies (Eng et al., 1991; Razum, 1993) do not provide support for this 
claim. 
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Results in the current study revealed that the majority (67%) knew that the vaccination 
mechanism was to mobilise the immune system. This would seem to be contrary to other 
studies, which suggested limited knowledge of how vaccines work (Angelillo et al., 1999; 
Tarrant & Gregory, 2001, White & Thomson, 1995 in Tarrant & Gregory, 2001). In a study 
conducted by Tarrant and Gregory (2001) on mothers' perceptions of childhood 
immunisation, results not only revealed the latter (i.e. limited knowledge of how vaccines 
work) but with mothers who also readily admitted that they had limited knowledge of how 
vaccines work. The majority of participants (67%) in this study described how vaccines work 
by making reference to terms like immune system and anti-bodies, at times explicitly 
referring to terms such as T-cells and memory cells. For example, one Science student 
explained it in the following way: 
"How they basically work is in the body you 've got the immune system and it has memory B-
cells and T-cells. The memory B-cells are those that, they get produced and they 've got a 
specific shape ... the T-cells are there and they can change shape. They are the ones that 
fight the infection... So once they vaccinate you... the body produces those memory B-cells 
which recognise the structure of that virus, so that next time the real virus comes already the 
B-cells will be there to attack." 
On the whole participants demonstrated a fair understanding of vaccine mechanism in general 
and the use of medical terms would seem to suggest a slightly more sophisticated 
understanding however this needs to be further investigated, as mere mention of terms does 
not necessarily imply understanding. A plausible explanation for this finding is the level of 
education as participants in the sample were fairly well educated. Several studies (Angelillo 
et al., 1999; Greenough, 1995; Zhang et al., 1999) have found that education was positively 
related to knowledge about vaccination and EPI knowledge. Furthermore, being in an 
institution of higher learning, the students in the current study may have access to 
information, e.g. Science students admitted that they received lectures on vaccination as part 
of their course work. 
Knowledge of diseases that are vaccine preventable 
The World Health Organisation (WHO) has embarked on the control of six diseases: 
tuberculosis, diphtheria, pertussis, tetanus, polio and measles, initiating EPI for immunisation 
of all children of the world and promising health for all (Schoub, 1989). The vast majority of 
participants (91%) in the current study were able to mention at least one common vaccine-
preventable disease. Similar findings were reported locally in a study conducted in Cape 
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Town. In the latter study 77% of the participants mentioned measles, 43% mentioned TB and 
a few knew about tetanus (Van Staden et al., 1995) as vaccine-preventable diseases. Similar 
results were also reported in two separate studies in Zimbabwe, one of which was conducted 
in a rural community and the other in an urban community, respectively (Razum, 1993; 
Woelk et al., 1986 in Van Staden et al., 1995) as well as in Ethiopia (Gedlu & Tesemma, 
1997). As in other studies, in the current study, measles was the most commonly mentioned 
vaccine preventable disease (Gedlu & Tesemma, 1997; Razum, 1993; Tarrant & Gregory, 
2001; Van Staden et al., 1995). 
In the present study many participants (57%) also incorrectly mentioned other diseases that 
are not in fact vaccine preventable. Specifically, malaria and chicken pox were the most 
incorrectly mentioned, as in other studies in Canada and South Africa, respectively (Tarrant 
& Gregory, 2001; Van Staden et al., 1995). 
Thus, it would appear that in both developing and developed countries there is a tendency to 
correctly mention one or two vaccine preventable diseases, with the exception of an Italian 
study in which participants were able to mention four mandatory vaccines (Angelillo et al., 
1999). This is often accompanied by a tendency to incorrectly mention diseases that are not 
preventable by vaccines. In developed countries in Europe (Angelillo et al., 1999) and North 
America (Tarrant & Gregory, 2001), knowledge of vaccine preventable diseases has been 
associated with education and age of the mother. However these variables were not explored 
in the current study. The results in the present study would seem to suggest that education on 
vaccine- preventable diseases is needed. It is important for recipients of vaccination services 
to know which diseases are vaccine-preventable so that people feel a sense of ownership of 
the vaccination process and are not threatened or feeling that vaccination is something they 
are coerced into (Van Staden, et al., 1995). 
Knowledge of HCWs views on vaccination 
Perceptions of HCWs have varied across different studies. In the current study perceptions of 
HCWs and their views on vaccination were predominately negative and indifferent. That is, 
70 % of participants stated that they were unsure what HCWs say, had never heard what 
HCWs say or that they don't explain about vaccination. Similar accusations have been 
levelled against HCWs in different parts of the world including Ethiopia (Gedlu & Tesemma, 
1997), Italy (Angelillo et al., 1999) and US (McCormick et al., 2001) both directly and 
indirectly. Although most participants (58%) in the current study relied on the medical 
system, e.g. clinics and hospitals, as their primary source of information, perceived support 
by the system was low. 
Results reported for a pertussis vaccination study conducted by Angelillo et al. (1999) 
revealed that 44.2% of participants reported no advice from HCWs. However, Zhang et al. 
(1999) reported that participants had confidence in their health care providers and 92.7% 
claimed they had received information from the same source. Low uptake of adult 
immunisation (36%) in the current study may be partially attributed to a lack of continuous 
education by HCWs, but this needs further investigation. Nonetheless the results suggest that 
perceptions of HCWs are negative or indifferent. 
Perceptions of vaccine target populations 
While numerous studies have indicated that participants across different contexts are familiar 
with the general purpose of vaccination (prevention) there is also evidence to suggest that 
some participants do not clearly distinguish between prevention and cure (McGrath, George, 
et al., 2001; McGrath, Mafigiri, et al., 2001). In the present study a very small minority (9%) 
did not clearly distinguish between prevention and cure when asked about the general 
purpose of vaccination. Parallel results were reported by Gedlu & Tesemma (1997) in which 
a small minority (3.4%) also stated that vaccines cure disease. When participants in this study 
were specifically asked whether a vaccine was for healthy (uninfected) or sick (infected) 
people, 82 % responded that it would be for healthy people and a minority (42%) replied that 
it was for sick people. After being prompted with a series of statements, McGrath, Mafigiri, 
et al. (2001) reported that 81% said that vaccines prevent disease and a majority (65%) also 
felt that vaccines cure a person. The results in the current study suggest that the 
understanding of the preventive notion of vaccination prevails, but that a minority may be 
confused about the role of vaccination in curing. It is also possible that participants may have 
been alluding to knowledge of the action of a therapeutic vaccine, which needs to be explored 
in future research. In addition, interviewer questions may have also contributed to 
participants' responses. 
Actual and preferred sources of information about vaccination 
As in other studies (Angelillo et al., 1999; McCormick et al., 1997) the present study found 
that clinics, hospitals and schools (i.e. HCWs, posters and pamphlets therein) were the most 
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commonly reported source of vaccination related information (58%). Other sources of 
information reported by participants in the current study included the media (21%) and 
friends or neighbours (15%). In other studies, mass media, pamphlets (Angelillo et al., 1999) 
family members involved with medical profession and other relatives (McCormick et al., 
1997) were also reported as sources of information about vaccination. In the present study 
media channels were the most preferred source of information (40%), followed by medical 
sources (such as HCWs - 21%) despite their bad review, indicating that participants still 
value interpersonal contact with medical personnel in being educated about vaccination. 
Forty three percent of participants collectively listed various interpersonal mediums for 
education about vaccination, namely HCWs, anyone with credibility and knowledge, and 
friends or neighbours. Overall the findings regarding sources of information would seem to 
suggest a combination of media channels and interpersonal input would be preferred. This 
notion is supported by other empirical studies that have focused on the impact of 
communication and education campaigns in changing both knowledge and coverage of 
vaccination (McDivitt, Zimicki & Hormk, 1997; Silva & Sorrell, 1984). As in Angelillo et al. 
(1999), the vast majority of current participants (88%) wanted to learn more about various 
aspects of vaccination. In both studies the knowledge of the general purpose of vaccination 
was good while knowledge of vaccine-preventable diseases was inconsistent. This suggests 
that more specific knowledge including knowledge of vaccine-preventable diseases is 
required. Research suggests that for people to effect appropriate health behaviour both 
general and specific knowledge is required (McDivitt et al., 1997). 
Reported barriers to vaccination 
Participants reported that lack of information, knowledge or education was the most common 
(70%) perceived barrier to vaccination, again reinforcing the need for continuous education. 
Several studies conducted in Africa (Gedlu & Tesemma, 1997) in Europe (Angelillo et al., 
1999) and North America (Tarrant & Gregory, 2001) have demonstrated the importance of 
knowledge or information (such as knowledge of vaccine preventable diseases, vaccine 
mechanism, vaccine efficacy, general level of education, and awareness of the need for 
repeated vaccination visits) on vaccination compliance. Other barriers mentioned in the study 
included concern about the physical or medical safety of vaccines, cultural or religious 
barriers, fears that vaccination may cause illness and logistical difficulties which were 
consistent with previous empirical findings (Durrheim & Ogunbanjo, 2000; Gedlu & 
Tesemma, 1997; McCormick et al., 1997; Pruitt et al., 1995). 
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Perceived alternatives to vaccination 
Results in the current study indicated that most participants, that is 73% (n = 24), believed 
that alternatives to vaccination do exist. Eight of these participants felt that alternatives were 
complementary while six felt that alternatives were better. The most commonly cited 
alternative (67%) to vaccination in the current study was health alternatives such as diet, 
sanitation and exercise, which was not found in empirical studies reviewed by the researcher. 
In the current study only 3% of the respondents made reference to cultural or religious 
alternatives, although 24% did mention culture or religion as a perceived barrier to 
vaccination. This was despite the fact that participants came from diverse language/ culture/ 
religious backgrounds. Lindegger and Wood (1995) purport that traditional healers in South 
Africa provide a much respected source of health related information outside of the western 
medical paradigm and command a great deal of support both in urban and rural black 
communities. Despite the fact that participants came from diverse religious backgrounds 
including those that might consult traditional healers, none of the participants mentioned 
religion as either an alternative or complement to vaccination. 
In a study conducted in Zimbabwe (Razum, 1993) it was found that while health personnel 
thought traditional and religious beliefs were to blame for low immunisation coverage, results 
could be explained by poor quality of EPI services. In addition, within these traditional and 
religious groups attitudes of members of such groups was changing, possibly due to social 
pressure from other mothers who complained that unimmunised children put their children 
who were vaccinated at risk (ibid). A significant minority (36%) in the current study felt 
alternatives were complementary. Similarly, in a study with Togolese mothers, the notion of 
protection through vaccination was reportedly in keeping with traditional practices of 
ancestors - preparing infusions with herbs and leaves or using fetishes to protect a child from 
disease (Eng et al., 1991). Eng et al. (1991) deduced that immunisations appear to be 
accepted as a present day supplement to, and not as a replacement for, traditional disease 
prevention practices. Furthermore, Odebiyi and Ekong (1982) found the combination of the 
measles vaccine with the traditional therapy of keeping tagiri in the house was acceptable. 
In summary, it is important to investigate alternatives to vaccination in order to disseminate 
knowledge of vaccination in a culturally sensitive manner and explore possible barriers. 
Results in the current study suggest more western medical alternatives such as health 
practices are more prevalent, possibly due to a well-educated sample such as in the current 
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study. As in other studies (Eng et al., 1991; Odebiyi & Ekong, 1982; Razum, 1993) the 
results of the current study also suggest that alternatives are perceived to be complementary 
to vaccination. 
5.2.2 Experiences of vaccination 
Various aspects of vaccination experience have been explored in empirical studies of 
vaccination uptake, compliance and vaccination history. In the current study responses to 
personal experience of vaccination were disappointing with most participants unable to 
clearly articulate their personal experiences. As only a minority (36%) had been vaccinated as 
adults in the current study it is not surprising that many could not give an adequate account of 
their own vaccination history. Findings in the present study suggest that uptake of childhood 
immunisation was high (88%). Other local studies revealed 80 -98% immunisation coverage 
in Hlablisa health district, kwa -Zulu Natal (Wilkinson et al., 1997) and 71.1% immunisation 
uptake in Mpumalanga province (Durrheim & Ogunbanjo, 2000). In a study conducted in 
China, immunisation coverage ranged from 89.3% in high service areas to 63.8% in low 
service areas (Zhang et al., 1999). In developed countries where there is a longer history of 
immunisation childhood immunisation has also tended to be high. In an Italian study for 
example (Angelillo et al., 1999), vaccination uptake for diphtheria, oral poliovirus and 
hepatitis B was high (94.4%) 
In this study uptake of adult immunisation was reportedly low (33%). This may also be 
partially attributed to the fact that participants had inconsistent knowledge of vaccine-
preventable diseases. In addition, when specifically asked about vaccination target none of 
the participants mentioned that they were for adults too with 36% specifically stating that it 
was mainly for children. Failure to obtain immunisation among various adult groups 
including healthy persons (Chapman & Coups, 1999), high- risk professional groups 
(Bodenheimer, Fulton & Kramer, 1986; Mckenzie, 1992; Zimet et al., 1997) patients 
(Fiebach & Viscoli, 1991) and elderly people (Zimet et al., 1997) has been reported in 
literature and reasons for this differ. The most common include perceived effectiveness of the 
vaccine and perceived likelihood of vaccine side- effects. 
In the current study a minority (24%) reported that vaccination had negative consequences. 
Although 36% reported side-effects such as discomfort or sickness participants also 
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recognised that it was an integral part of vaccination and did not explicitly present this as a 
significant deterrent. Tarrant & Gregory (2001) described how participants reported that their 
children had experienced vaccine side-effects such as fever, irritability, pain, swelling and 
redness at the injection site. As in the current study most mothers were prepared for these 
side-effects, which did not prevent them from having their children immunised (Tarrant & 
Gregory, 2001). Similarly, Angelillo et al. (1995) reported that about half of the participants 
(45%) correctly believed that the undesirable side-effects of vaccination are an important 
determinant of their value. 
5.2.3 Knowledge and expectations of HIV vaccination and participation in a 
hypothetical vaccine trial 
Knowledge and expectations of potential vaccines 
Assessing community knowledge about vaccines in general and clinical trials specifically is 
an important aspect of the preparatory phase of vaccine trials. This is important in order to 
meet the educational needs of potential South African participants both at a community and 
individual level and in ensuring adequate information campaigns and informed consent 
procedures. In the current study the majority of participants (70%) correctly reported that 
HIV was a dangerous disease for which there is no vaccine while a small minority, that is 
12% (n = 4), were under the misconception that there was an already existing HIV vaccine, in 
the form of antiretroviral drugs. Conversely, in a study conducted in Uganda, which assessed 
community knowledge and attitudes to HIV vaccination in 56 communities (10 848 
participants) in preparation for HIV vaccine trials, 67% of participants incorrectly believed 
that HTV vaccines were already available (Kiwanuka et al., 2000). Paradoxically, results in 
the current study indicated that participants did not have extensive knowledge of the pending 
HIV preventive vaccine trials and efforts to develop a safe and effective vaccine locally. 
Specifically, about half of the participants (52%) had never heard of possible HIV vaccine. A 
minority of participants in the present study (36%) had heard of a possible HIV vaccine. 
Similarly, Kiwanuka et al. (2000) reported that 41% of participants knew that HIV vaccines 
were being tested. This points to the need to increase efforts to inform the lay public about 
upcoming HIV vaccine trials. In contrast, in a study conducted in Thailand to determine the 
WTP in a HIV vaccine trial including, female commercial sex workers (n = 215), men 
attending sexually transmitted disease clinics (n = 219), conscripts in the Royal Thai Army (n 
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= 1453) and men discharged from the army (n = 293) who had returned to civilian life, 
revealed a common awareness of ADDS vaccine development efforts (62% - 77%) 
(Celentanoetal., 1995). 
In the current study general awareness of efforts to develop HIV vaccination was fairly low 
(36%), with as many as 45% of the participants who speculated that it would be for 
prevention and 39% of participants believed it would be for mainly HIV negative people 
(uninfected people). None of the participants (n = 0) explicitly stated that it would be for 
treatment although a small minority (24%) believed it would be mainly for HIV positive 
people (already infected people). This is in keeping with a key assumption of the current 
study, which is HIV vaccination would be seen as extensions of other familiar vaccination or 
health protective practices (Slack et al., 2000) that could be surveyed. This may be 
considered good news for researchers involved in the pending HIV trials, which are 
preventive in nature. In contrast, McGrath, Mafigiri, et al. (2001) reported that when 
participants were asked an open-ended question regarding who should participate in a vaccine 
trial, 35% of participants stated that infected persons should participate. In the latter study, 
when specifically asked if a vaccine was for infected or uninfected persons a significant 
minority (38%) said it was for infected persons, the primary reason being that infected 
persons could benefit from a vaccine (ibid). Moreover, the results in the current study suggest 
that more vigorous community awareness needs to be created and the specific nature of 
preventive vaccines reinforced. 
Stated WTP in potential HIV vaccine trials 
Assessments of willingness to participate (WTP) in different communities could provide 
researchers with an indication of level of recruitment required, and informational 
requirements needed for adequate education campaigns and informed consent procedures. 
Although the results in the present study are not generalisable to all persons likely to be 
recruited, or the wider South African population (see section 5.4) and the assessment of WTP 
did not include all necessary elements, the results still have implications for future research 
into WTP in South Africa. The 'stated' WTP in this study may provide preliminary data from 
which more formal WTP can be assessed. 
In the present study WTP was measured as a dichotomous outcome (willing or not willing). 
In this respect 30 % of participants stated they were willing, 33% of participants were not and 
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15% were unsure. These findings compare with other studies, where assessment of WTP did 
not include an informational or educational component on HIV vaccines and trials. For 
example, locally in the Western Cape where 20% stated WTP (Moodley, Barnes, van 
Rensburg & Myer, 2002), in Northern Thailand where 25% of participants stated WTP 
(Celentano et al, 1998 in MacQueen, 1999), and New York America where 27% of 
participants stated WTP (Koblin et al., 1998 in MacQueen, 1999). Other empirical studies 
that collected data from diverse as well as homogenous groups in Northern and Southern 
Thailand and different parts of America indicated that those definitely WTP ranged between 
20% and 50% at baseline. Results less than 20% may suggest poorly defined motivations, 
incentives or benefits for participation in the community (Koblin et al., 1997; MacQueen, 
1999). Those not at all willing to participate ranged from 3% to 9% of people surveyed. 
Results greater than 10% may indicate significant underlying barriers that need to be 
identified and addressed prior to attempting an efficacy trial (ibid). More recently, in Uganda 
where the first African trial of a candidate vaccine was conducted, much higher levels of 
WTP (69% - 79%) were recorded and those not willing to participate ranged from 13% to 
22% while those not sure ranged from 4% to 14% (McGrath, George, et al., 2001; McGrath, 
Mafigiri, et al., 2001). The high level of WTP in the latter studies is particularly interesting 
considering the history of clinical research conducted in Africa in general (as discussed in 
section 2.7.2) and more specifically the initial ethical concerns raised by the Uganda network 
on law, ethics and HIV regarding the informed consent process, possible coercion of 
volunteers, reimbursement and volunteer' confidentiality (Mugerwa et al., 2002). Participants 
in the current study fell within the range 20% to 50%, as 30% of participants stated 
willingness to participate even though their level of awareness of the pending HIV vaccine 
trials was fairly low (36%). On the one hand this may be good news for researchers in the 
field as this suggests that local results on WTP may be consistent with those in other 
communities surveyed for HIV vaccine trials. On the other hand it raises ethical questions 
regarding informed consent if people are 'willing' to participate despite being ill informed. 
Either way the results of the current study are not generalisable but point to avenues for 
future research. 
Paradoxically, it was anticipated that WTP would be higher in the current study because 
information about HIV vaccines was not given and most participants had never heard of 
possible HIV vaccine before being interviewed. This assumption was based on the fact that 
empirical studies have shown that with additional information (and time) WTP decreases -
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but stabilises about a year after first introducing the idea of vaccine trials (Bartholomew et 
al., 1997; Jenkins et al., 1995; Koblin et al., 2000, Moodley et al., 2002). Thus, seeing as 
most participants were hearing about possible HTV vaccines for the first time, the researcher 
expected that WTP would border on the upper limit of the range 20% -50 %. A possible 
explanation could be that other intervening variables, which were not measured in the current 
study, contributed to the results. That is, the decision whether to participate or not is a 
complex function of a number of factors in a person's life, including among other things 
perceived risk of HIV infection due to behavioural and environmental factors, comprehension 
of how the trial works, peer influence, and trust in those implementing and supporting the 
trial (MacQueen, 1999), which were not explored in the current study. 
WTP was not adequately explored but rather general issues (perceived barriers and 
incentives) were raised with the intent of providing more specific questions to be explored 
with a more generalisable sample in future research. These general issues included most 
importantly perceived incentives, barriers and concerns about trial participation. 
Perceived incentives for trial participation 
As in research conducted by Jenkins et al. (1995) the current study differentiated between 
personal incentives and perceived incentives for others. Although most of the incentives 
between the two categories were consistent, their prioritising differed. Most markedly, 
altruism was the most commonly stated personal motive while none of the participants 
mentioned altruism as a perceived incentive for others. The possibility of social desirability 
by the participants cannot be out-ruled. That is, participants may have stated what they 
perceived would be a socially desirable motive to the researcher, in order to please the 
researcher with their personal 'unselfish' motives. Jenkins et al. (1995) found that perceived 
benefits to self were associated with WTP, while altruism items were not related to WTP. 
As with US, Thailand and African settings, altruism and opportunity to reduce personal risk 
for HIV infection were popularly cited incentives for participation in vaccine trials in the 
current study (Koblin, et al., 1998; MacQueen, 1999). McGrath et al. (1997) reported a 
'desire for cure' if respondents became infected as the second most common reason for WTP 
in their vaccine study. The other incentives in the present study were also common to other 
empirical studies such as recognition or acknowledgement, compensation and medical 
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benefits - e.g. guarantee of medical care or counselling (Celentano et al., 1995; Koblin et al., 
1998). 
Perceived barriers and concerns about trial participation 
The concerns and barriers associated with possible vaccine trial participation also parallel 
those found locally (Moodley et al., 2000) and elsewhere (Celentano et al., 1995; Jenkins et 
al., 1995; Koblin et al., 1998). The most common included significant physical risk 
(Celentano et al., 1995; Jenkins et al., 1995; Koblin et al., 1998), psychosocial risk such as 
social discrimination or stigmatisation (Jenkins et al., 1995; Koblin et al., 1998) and 
questionable efficacy of vaccination (Koblin et al., 1997). Unlike other empirical studies 
reviewed by the researcher, a significant minority of participants (39%) felt that affordability 
may be another possible barrier. In the words of one participant: "I'm aware it has to do with 
class. Some people will afford it and others won't. But maybe as time goes on everyone 
should get access..." This is a poignant point considering the economic imbalance that 
apartheid has caused on health issues in South Africa. Both the incentives and barriers to 
participation need to be addressed in order to enhance the level of WTP but also to ensure 
adequate informed consent. 
5.2.4 Demographic variables associated with knowledge and experiences of 
vaccination 
Results in the present study revealed that knowledge of vaccination (purpose, mechanism, 
and vaccine target) was not associated with gender or with motherhood. In addition, no 
significant differences were found between experiences of vaccination (uptake of vaccination 
and side effects experienced) and gender, and between experiences and motherhood. In 
general, knowledge has been shown to differ along the following demographic variables: age 
(Angelillo et al., 1999; Van Staden et al., 1995); education (Angelillo et al., 1999; Zhang et 
al., 1999); socio-economic status (Odebiyi & Ekong, 1982; Zhang et al., 1999); access to 
health insurance; and exposure to information sources (Zhang et al, 1999). Thus, it could be 
argued that the present results are not necessarily startling, as gender has not been clearly 
demonstrated to impact on knowledge of vaccination while motherhood per se has not been 
widely investigated. One can possibly deduce that while knowledge has been shown to differ 
along demographic lines, this trend is not necessarily universal but context specific. This may 
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also indicate that in a 'well' educated sample such as this, there might be more homogeneity 
with regard to certain aspects of knowledge and experiences with vaccination, but not all. 
Specifically, results in the current study indicated that regarding knowledge of vaccine -
preventable diseases, mothers were less likely than non-mothers (p =. 045) to be aware that 
HIV has no vaccine. This may suggest that mothers were more likely to hope for an existing 
HIV vaccine. Perhaps this can be partially attributed to the fact that traditionally mothers 
have been caregivers and therefore have a vested interest in the health of their offspring. This 
is particularly interesting considering that mothers were more likely than non-mothers (p =. 
034) to say that they had heard of a possible HIV vaccine. 
Significantly less mothers than non-mothers (p =. 034) expressed WTP in HIV vaccine trials. 
In the words of one mother: "... It's never been tried on anyone I know of and I don't know 
how it works. I don't want to be the first...". One possible explanation could be that with the 
uncertainty of risks involved most mothers would be unwilling as it might impact on their 
'mothering' (if they got sick for example). Significantly less mothers than non-mothers (p =. 
017) were likely to report personal feelings of altruism. A possible explanation is that 
humanitarian feelings to future generation may be precluded by need to focus on their 
children and the status quo. This is consistent with the fact that most mothers were not WTP. 
This also suggests that most mothers were less likely to be influenced by social desirability 
regarding their participation. 
Significantly less females than males (p = .022) were concerned about psychosocial risks, 
such as increased reckless sexual activity and stigmatisation. This suggests that females were 
less likely to perceive themselves to be at psychosocial risk, which needs to be explored in 
future research. 
5.3 Limitations of the study 
The results of the current study sampling 33 participants non-randomly cannot be generalised 
to the general population of persons likely to be enrolled in trials, or the South African 
population in general. However, the results may be extrapolated to one subset of the 
population being targeted for trials. University students from the University of the 
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Witswatersrand have been recruited for HTV vaccine trials in South Africa (C. Slack, 
personal communication, October 16,2003). 
The general aims of the study were exploratory in nature, and set out to explore knowledge, 
perceptions and experiences of vaccination. In so doing more precise questions for future 
research and education could be identified. The aim of the current study was therefore not to 
produce generalisable findings. However, in the future the findings of this study may be 
compared to similar studies currently being carried out in different South African 
communities (da Silva, 2003; Lindegger et al., 2003) in order to assess the generalisability of 
specific results. 
Sampling was expedited by convenience sampling due to time constraints and a small 
number of participants were recruited. Even though the sample size was small, a degree of 
purposive sampling (which selects information rich cases) was utilised and the researcher 
stopped data collection after interviewing reached a point of saturation. That is, no new 
information was yielded. 
The current research was not interested in the incidence of responses but also in the quality of 
responses given by participants. Due to the small sample size the power of Chi-square test 
can be considered as fairly low in the current study. However, Chi-square test was used to 
complement the predominately interpretive content analysis and investigate possible 
relationships between certain demographics and codes, which may be significant in a more 
generalisable sample. 
The value of the research design in the current study is that it used open-ended interviews to 
identify perceptions inductively (and not just merely reduce participants' responses to 
numbers), complemented by the use of quantitative methods, which were used to assess how 
widespread perceptions were. 
Interviewer bias cannot be ruled out in the current study. Specifically, when the researcher 
introduced the project to participants as part of the 'HTV vaccines' ethics group, this may 
have oriented responses in a certain direction. In addition, some of the questions may have 
introduced bias. For example, 'Do vaccines prevent or treat illness? Is vaccination for 
infected or uninfected people'? 
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In the current study, informational provision consistent with robust measures of WTP in a 
hypothetical HIV vaccine trial, were not fully met. In addition, WTP was predominately 
measured as a single dichotomous outcome (willing or not willing) whereas some studies 
have used a combination of dichotomous and scaled (e.g. definitely willing, probably willing, 
probably not willing, not willing at all) outcomes. Therefore direct comparison with these 
studies is limited. Instead in the current study general issues were explored with the intention 
of providing more specific questions for future research in South Africa. 
5.4 Implications in HIV vaccine trials 
5.4.1 Implications for education 
Results in the current study revealed sound knowledge of vaccination in general. However, it 
was also apparent that there is a need for continuous education. Specifically, data from this 
study suggests the following components be included: 
Vaccination in general 
> The purpose of most vaccines is to prevent disease. 
> Healthy people receive preventive vaccines. 
> Vaccines prevent disease by mobilising the body's defence system, better known as 
the immune system. 
> Vaccines sometimes cause side-effects, which are an important determinant of their 
value. 
> Vaccines do not cause illness or death. 
> Vaccines do not guarantee immunity but significantly reduce susceptibility to disease. 
> Vaccines sometimes fail. 
> Vaccines are disease specific and therefore any given vaccine targets a specific 
disease. 
> Examples of vaccine-preventable diseases include: polio, measles, mumps, rubella, 
diphtheria, pertussis, tetanus, Haemophilus influenzae b, hepatitis A & B, influenza, 
yellow fever and rabies. 
> Not all diseases have a vaccine. 
> There is currently no vaccine for malaria, chicken pox and HIV. 
> Although most vaccines are given to children, vaccines are also given to adults. 
Vaccine trials 
> A preventive HIV vaccine is going to be tested in South Africa on (different) 
volunteers. 
> The trial will be a controlled trial and therefore some volunteers will receive the 
vaccine while others will receive an inactive substance called a placebo. 
> Some people will become HIV positive during the trial for the same reasons that other 
people would, e.g. from unprotected sex. 
> More infections in persons who received the placebo would indicate that the vaccine 
is working. 
> Participants will have to be available to receive injections throughout the study. 
> Only healthy people who are HIV negative will be able to volunteer. 
> The HIV vaccine will not guarantee immunity to HIV infection. 
> A preventive HIV vaccine may prevent disease, delay progression of disease or reduce 
transmission of infection. 
As the current study was interested in general issues, WTP was not adequately assessed. 
Future research conducted on a more generalisab 1 c sample therefore requires more formal 
assessment of WTP. The most useful assessment of potential WTP would include 
comprehensive education, which would be available during actual recruitment for trial 
(MacQueen, 1999). In a guide for assessment of WTP in preventive HrV vaccine efficacy 
trials prepared by MacQueen (1999) for UNAIDS, the following informational requirements 
are suggested: basic elements of controlled clinical trials, vaccine concepts, medical risks, 
social risks, behavioural risk reduction and benefits of participation and trial sponsorship. 
5.4.2 Implications for future research 
The results from the current study suggest the following are important issues to be explored 
and further researched as perceived barriers and incentives for trial participation: 
Incentives 
> By participating you will be helping your community (altruism). 
> If you participate you will receive compensation for research- related injury. 
> By participating you will receive acknowledgement (recognition). 
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> If you participate you will receive free HIV tests at a time that is convenient to you 
(medical benefits). 
> By participating you will receive counselling to reduce risk (opportunity to reduce 
personal risk). 
Barriers 
> The long-term side effects of a possible HIV vaccine are not known (significant 
physical risk). 
> Your family and friends might think it is a bad idea for you to be in a HIV vaccine 
trial (psychosocial risk). 
> It is not clear how expensive the vaccine will be (affordability). 
> The vaccine is experimental and it is not clear if it will work (questionable efficacy of 
vaccine). 
> If you participate you will have to be vaccinated with a needle and bloods taken at 
every visit for a number of years (fear of re-used needles). 
It is also imperative that in future WTP research, all participants not only receive adequate 
information but that the elements that impact on their decision are properly measured. 
According to MacQueen (1999) the following elements should also be included in an 
assessment of WTP, some of which were not included in the present study: 
> Sociodemographic characteristics of participants, which at a minimum should include: 
age, sex, race/ethnicity, religion, marital status, employment or occupation, income, 
education or literacy, residential stability and information on HIV-related risk 
behaviours. 
> Comprehension of key concepts of a trial. 
> WTP that is either a dichotomous outcome (willing or not willing) or scaled responses 
(e.g. definitely willing, probably willing, probably not willing, not willing at all). The 
latter allows for researchers to understand the amount of ambiguity and direction 
(positive or negative) of responses. 
> Statements of incentives and barriers that are either conditional measures of WTP or 
independent measures. 
> Motivations, incentives, and barriers that reflect realistic perceptions and do not 
mislead prospective participants in anyway. 
> Social networks and community context of prospective participants that may impact 
on an individual's decision-making process. 
As the current study was exploratory and used a small non-random sample, the 
generahsability of the results was limited. MacQueen (1999) suggests that a sample size of 
200 is sufficient to complete a statistically valid assessment of WTP for a relatively 
homogenous population - with regards to factors that are likely to influence WTP such as 
sex, sexual orientation, risk behaviour, age, socio-economic class, ethnicity, race, education 
and sources of income. 
Chapter 6: CONCLUSION 
In preparation for HIV vaccine trials in South Africa, the current study had four primary 
objectives. Specifically, the study set out to assess students' knowledge and perceptions of 
vaccination in general, including perceived barriers to vaccination. Secondly, students' 
experiences with vaccination were assessed. Thirdly, and more specifically the study assessed 
students' knowledge of, and expectations toward HIV vaccination and participation in a 
hypothetical vaccine trial. Finally, the study explored if particular knowledge and experiences 
are associated with demographics, such as motherhood and gender. In accordance with the 
objectives of the current study and despite design limitations, the following conclusions can 
be drawn. 
The results of the current study revealed that the vast majority of participants knew the 
general purpose of vaccination and nearly half of the sample speculated that a prospective 
HIV vaccine would be preventive in nature. This indicates that the purpose of vaccination 
was familiar amongst students, which is good news for HTV vaccine researchers. 
However, the results of the present study showed that besides infant and childhood 
immunisation, other forms of preventive practices (such as adult vaccination) were unfamiliar 
practices among the participants. This is contrary to a position put forward in Chapter 1, 
which posited that given South African's longstanding history with vaccination in general, 
HIV vaccine trials might not be seen as an alien concept in communities but rather as 
extensions of familiar health practices. These results suggest that more extensive awareness 
of the HIV vaccine trials is required. 
Another pretext of the current study was to identify important health beliefs that might aid 
local researchers to conduct further research in a culturally sensitive manner. Although 
culture and religion were stated as perceived barriers (by a minority) no personal examples 
were forthcoming. Instead the majority of the sample reported perceived alternatives to 
vaccination indicating that more western medical health practices were more prevalent, which 
may be attributed to the urban setting and well-educated student sample status. These results 
suggest that culture and/ religion may not be significant barriers to HIV vaccine trials. This 
needs to be investigated further in future research. 
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Given that similar numbers of participants stated that they were either WTP or not WTP in a 
hypothetical vaccine trial, motivations for participation will need to be further explored in 
future research in order to ensure that sufficient numbers of volunteers are recruited on the 
one hand but also that the process of recruitment is ethically sound. 
The results imply that a number of concepts are important for education including: there is 
currently no vaccine for malaria, chicken pox and HIV; vaccines are for both adults and 
children; a preventive HIV vaccine is going to be tested in South Africa, and only healthy 
people who are HIV negative will be able to volunteer. The results also imply that 
participants' motivations for participation in a HIV trial will have to be assessed as they 
impact on the decision to participate or not. Finally, the results of the current exploratory 
study are not only important because they relate to an area of research that may lead to a 
possible breakthrough in HIV pandemic, i.e. the advent of HIV vaccine trials, but it also 
highlights the need to be continually ethical. This is especially important in South Africa 
where undermining of human rights was legitimised in the 'not so' distant political past. 
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Vaccination study: An exploratory study of students' knowledge, experiences and 
attitudes toward vaccines 
Information sheet 
1. Description of study 
A. Purpose 
This study broadly aims at exploring the knowledge, experiences and attitudes of South African 
students toward vaccines. It aims to elicit information on students' understandings of vaccines and 
how they work. It also examines students' attitudes and subjective experiences of vaccination. 
B. Background 
In general there appears to be scarce information on indigenous knowledge, attitudes and experiences 
with vaccinations generally. It is hoped that this study will better inform us about people's 
understandings on how vaccines work. 
C. Specific location of study 
This study is part of a larger vaccination study conducted by a project based at the school of 
Psychology at the University of Natal, Pietermaritzburg. Interviews will be conducted in designated 
rooms at the School of Psychology and university residences. 
D. Probable duration of project 
All interviews will take place after July 23,2001 and prior to April 31,2003. 
E. Research plan 
Data will be gathered through semi-structured interviews, conducted with diverse South African 
students from Natal University. These interviews will focus on the students' knowledge, experiences 
and attitudes toward vaccines. Data will be analyzed using content analysis and qualitative data 
analysis methods such as thematic coding. 
I l l 
II. Human participants 
A. Subject population, recruitment 
Volunteers will be gathered from various faculties and residences at the University of Natal. Both 
males and females will be targeted. The sample will comprise of approximately SO students. Sampling 
will be used to ensure a representative sample reflective of the gender and race variables. Attempts 
will be made to include a diverse range of students. 
B. Risks 
The study has minimal risks. It is perceived that stigmatization as a result of participation will be 
insignificant in this study as it is a general vaccination study as opposed to an ADDS survey in which 
stigmatization may occur. A possible risk is inconvenience and loss of time. 
C. Informed consent procedures 
Each participant will be required to have read this information sheet before interviewing can begin. 
The prospective participants will be allotted time to ask questions about the nature of the study in 
order to ensure full comprehension. Participants will be further required to give written permission 
acknowledging that they have been adequately informed about the study and the conditions thereof. 
Participants will be requested to sign a separate consent to the interview being tape-recorded. In the 
event that the subject does not consent to tape-recording, extensive notes will be made with reference 
to the participant's responses. Participants are also free to abandon the interview at any point. 
D. Protection of participants 
Interviews will be conducted in the privacy of a closed room. Each participant will be assigned a 
code, and all interview schedules will remain anonymous. Each tape-recorded interview will be 
identified only by the participant's code, and no names or identifying characteristics will be used 
during the interview. Participants will be fully informed that the goal of this research project is not to 
evaluate the adequacy of their knowledge and/or relative experience with vaccines. All data, including 
tapes of recorded interviews and transcripts, will be securely stored. 
E. Potential benefits 
The study will provide the participants with an opportunity to explore their own understanding of 
vaccines. 
F. Costs to subject 
Other than time, the participants involved in the study will incur no financial costs. 
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INFORMED CONSENT FOR INCLUSION IN THE VACCINATION STUDY 
I, (Name) 
hereby consent to be interviewed and to participate in this vaccination study. 
I acknowledge that I have been informed by: 
concerning the possible advantages and possible adverse effects, which may result from 
the abovementioned interview. 
I agree that the above interview will be carried out by 
I acknowledge that I understand the contents of this form and freely consent to the 
abovementioned interview being conducted on me. 
I agree that this interview will be treated with strict confidentiality and anonymity. I only 
agree for the information I give to be published and used in advancing other peoples' 
knowledge. 
I acknowledge that I may leave this interview any time I feel like doing so. 
Signed (participant): Date: 
Signed (researcher): Date: 
I agree to the fact that this interview will be tape-recorded. 
Signed (participant): Date: 
Signed (researcher): Date: 




VACCINATION STUDY SEMI-STRUCTURED INTERVIEW SCHEDULE 
A. DEMOGRAPHIC I BIOGRAPHICAL INFORMATION 
1. Gender: MaleD Female D 
2. How old are you? 
3. What is your home language? 
14 - 20 D 
41 - 50 • 
;



















4. What is your highest educational qualification? 
Std 6 -10 /Secondary D 
Post school tertiary diploma D 
Tertiary degree D (specify) 
5. What degree are you currently studying? 
6. Are you employed? Part time / full time 
Yes D No D 
6. What work do you do? 
7 (a) Are you a member of a religious group or body? Yes D No D 
(b) If your answer is 'Yes", please give the name of the religious group or body you belong 
to. (E.g. Methodist, Roman Catholic, Islamic, African Traditional, ZCC 
etc) 
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B. VACCINATION QUESTIONS 
Question 1 (general) 
1.1 Please tell me what you know about vaccination. 
1.2 Why do people get vaccinated? What is the purpose of vaccination? 
1.3 Where have you heard about vaccinations? 
1.4 Have you been vaccinated? 
1.4.1 If so, what for and when? 
1.4.2 What do you remember about your experience of vaccination? Was it helpful, helpless, 
painful, worth taking, etc? 
1.4.3. Have you been vaccinated since childhood? Why? 
If so, for what were you vaccinated? What was your experience? (Optional) 
1.5 Have your children been vaccinated? 
1.5.1 If yes, how did it come about that they were vaccinated? 
1.5.2 What sort of experience did they have of being vaccinated? 
1.6 Do your friends and family go for vaccination? Why? 
1.6.1 Do any of them not go? For what reasons? 
1.7 What do nurses/ doctors say about vaccination? 
1.7.1 Do you believe it? Why? 
Question 2 (vaccination function and mechanism) 
2.1 What does vaccination do? 
2.1.1 What can it prevent? What can it protect against? 
2.1.2 Can you tell us how the vaccine works? (How do vaccines work? / What does it do in 
the body?) 
2.2 Do you think that vaccination can prevent infection or disease? 
2.3 Can you name any diseases that you think vaccines protect against? 
2.4 What dangerous diseases do you think they do not protect against? 
2.5 Do you think vaccination can also be used as treatment? Why is this? 
2.6 Do you think a vaccine can cure the illness? How would it help already infected people? 
Question 3 (vaccination recipients) 
3.1. Who do you think should be vaccinated? Why? 
3.2 Is vaccination for adults or children or both? Please explain your answer. 
3.3 Should healthy people be vaccinated? Why? 
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3.4 Should already infected people be vaccinated? Why? 
Question 4 (vaccination problems/ barriers) 
4.1 What do you think are some of the problems of immunization? (Why people would not 
go?) 
4.2 What things may stop some people from getting vaccinated or having their children I 
vaccinated? Why do you think this is the case? 
4.3 We have heard some people say that vaccination can cause illnesses, or difficulties, what 
do you say about this? Have you heard such things? What exactly have you heard? (How do 
vaccines cause illness?) 
4.3.1 What would you suggest should be done to eliminate such difficulties? Why? 
Question 5 (alternatives) 
5.1 Are there any other ways of stopping yourself and / or your family from getting sick? 
5.2 If yes, can you tell me about these? 
5.3 Are these measures better or worse than vaccines? Why? 
Question 6 (immunisation services and health care workers) 
6.1 Are immunization services offered at your nearest clinic? 
6.2 How do the staff and nurses there encourage you to be vaccinated? 
6.2.1 What do nurses explain about how vaccines work? 
6.3 What do you think would make it easier for people to get vaccinated? 
Question 7 (vaccination and the law) 
7.1 Do you think that there should be a law forcing people to be vaccinated? 
7.2 If yes, why should people be forced to vaccinate? What about their human rights? 
7.3. If no, why is this? Please explain. 
Question 8 (information needs) 
8.1 Would you like to know more about vaccination? 
8.2 If yes, what would you like to know more about? 
8.3 Why do you think this is important to know about? 
8.4 How would you like to receive this information (probe i.e. nurses, community leaders, 
other members of the community disseminating information etc)? 
Question 9 (HIV vaccination) 
9.1 Have you ever heard of an HTV vaccine? Please tell me what you know about it. 
9.2 Who will it be for? Will it be for healthy people (9.2.1 prevention) or HIV infected people 
(9.2.2 treatment)? 
9.2.1 If it will be for healthy people, what will it prevent, infection or disease? 
9.2.2 If it will be for HIV infected people, what do you think vaccines do to already infected 
people? 
9.4.1 If you were asked to participate in research on HIV vaccines, how would you feel 
about this? 
9.5 What do you think prospective participants would want to know before volunteering? 
9.5.2What do you think prospective participants would want in return for participating in 
such research? 
9.5.3 What would be some of their fears? 





Coding schedule for vaccination study 
Format: 
An X indicates that the line is a heading, not a code. 
Any number of codes may apply to a single sentence. 
In certain instances, a higher- level code should be used if you cannot glean 
sufficient information from the text to use a lower level code. E.g. If 
participants have heard rumours of negative effects, but do not indicate 
whether those claims are believed or not, then code at 3.2.2. 
Code 20 if any important information cannot be coded according to this 
scheme at your discretion. 
1. X Understandings of official views 
1.1. X What do people say that medical practitioners (health care workers) say? 
1.1.1. Unsure of what medical practitioners say 
. 1.2. Never heard what medical practitioners say 
.1.3. What medical practitioners say is helpful 
. 1.4. Medical practitioners say vaccines preventative 
.1.5. Medical practitioners say vaccines required for proper care for children 
. 1.6. Medical practitioners say; are a way of taking care of lives, are helpful, good 
for you 
. 1.7. Medical practitioners say that people have a right to be protected 
.1.8. Medical practitioners say that vaccinated people are strong and healthy 
. 1.9. Medical practitioners just want to know children's vaccination schedule (don't 
explain) 
.l.lO.Medical practitioners say vaccines are compulsory 
.1.11.Medical practitioners don't explain/ don't say anything 
2. X Do people believe what medical practitioners say? 
2.1. Yes, believe what medical practitioners say. 
2.2. The advice of medical practitioners is trustworthy 
2.3. No, do not believe what medical practitioners say 
2.4. Personal experience confirms health-care worker's view 
2.5. Important to confirm official views 
2.6. Dissatisfied with what health care workers say (e.g. because no-one explains) 
2.7. Distrust anything that is free 
2.8. Unsure/ Ambivalent 
3. X Attitudes towards vaccination (Positive/Negative) 
3.1. X Vaccination helpful 
3.1.1. Vaccinations medically helpful 
3.1.2. Facilitates admission to school 
3.1.3. Other ways of vaccination being helpful. 
3.2. X Rumours of Negative effects 
3.2.1. Have not heard claims of negative effects 
3.2.2. Have heard claims of negative effects 
3.2.2.1. Heard claims of negative effects and believe them 
3.2.2.2. Heard claims of negative effects but do not believe them 
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3.2.3. Rumours/Claims of negative effects - Other 
3.3. X Side-effects 
3.3.1. None (vaccines don't have side effects) 
3.3.2. Yes, vaccines have side effects 
3.3.2.1. Discomfort (pain, swelling, fever, fatigue) 
3.3.2.2. Loss of appetite 
3.3.2.3. Sickness 
3.3.2.4. Other 
3.3.3. Side-effects show that vaccine is working 
3.3.4. Side-effects due to pre-existing infections 
3.3.5. Side effects show that vaccination is making illness worse 
3.3.6. Side-effects signal problems with vaccines 
3.3.7. Side-effects - other 
3.4. Interferes with traditional measures of disease treatment and prevention 
3.5. Unhelpful (e.g. because disease caused by spiritual factors) 
3.6.People who fail to vaccinate are careless/ reckless/ stupid (negative attitude towards 
people who do not vaccinate) 
4. X Vaccine target 
4.1. All people 
4.2. X Specific categories 
4.2.1. Target: Children (mainly) 
4.2.2. Target: Adults (mainly) 
4.2.3. Target: Children or adults 
4.2.4. Target: Unsure about adults 
4.2.5. Target: Women (mainly) 
4.2.6. Target: Sexually active people (14-25) 
4.2.7. Target: Men (Mainly) 
4.2.8. Target: HIV+ people only 
4.2.9. Target: Healthy people 
4.2.10. Target: Unhealthy people 
4.2.11. Target: People at risk (From HIV, local epidemics etc.) 
5. X What do vaccines do? 
5.1. Vaccines prevent illness 
5.2. Vaccines maintain or promote health 
5.3. Vaccines treat illness 
5.4. Vaccines treat & prevent illness 
5.5. Vaccines are not a treatment 
5.6. Protect against disease, but are not necessarily full proof (e.g. might still get sick, not 
100%) 
5.7. Cures disease 
5.8. Does not cure disease 
5.9 Vaccines have no purpose 
5.9.1.Protects against infection (not disease) 
5.9.2.Protects against both infection and disease 
6. X Vaccination Mechanisms 
6.1. Unsure of vaccination mechanisms 
6.2. Vaccines make you strong 
6.3. Vaccines fight Disease 
6.4. Vaccine myths (e.g. vaccines cleanse the blood) 
6.5. Vaccination Mechanisms - Other 
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6.6. Trigger and stimulate immune system 
7. X Specific Diseases that vaccines prevent 
7.1. Vaccines prevent: Common vaccine-preventable diseases (measles, smallpox, polio, 
flu etc.) 
7.2. Vaccines prevent: Other specific diseases (e.g. cancer, malaria, arthritis, bilharzias 
etc..) 
7.3. Vaccines prevent: All or any diseases 
7.4. Vaccines prevent: HIV 
7.5. Vaccines do not prevent: common vaccine-preventable diseases (measles, smallpox, 
polio, flu etc.) 
7.6. Vaccines do not prevent: Other specific diseases (e.g. cancer, malaria, arthritis, 
bilharzias etc..) 
7.7. Vaccines do not prevent: All or any diseases 
7.8. Vaccines do not prevent HIV (prevention) 
8. X Personal Experience of Vaccination 
8.1. Yes have been vaccinated 
8.2. No has not been vaccinated 
8.3. Clear knowledge of own vacc. history 
8.4. Unclear, or no knowledge of own vacc. history. 
8.5. Personal experience of Vaccination: Vaccination Helpful 
8.6. Personal experience of Vaccination: Vaccination unhelpful 
8.7. Personal experience of Vaccination: Vaccine had side effects 
8.8. Personal experience of vaccination: Negative consequences (effects) of vaccination 
8.9. Participant vaccinates children 
8.9.1. Participant vaccinates children : To protect 
8.9.2. Participant vaccinates children : To prevent disease transmission 
8.9.3. Participant vaccinates children : Unsure 
8.9.4. Participant vaccinates children : Other reasons 
8.10.1. Children's experiences of vaccination: Vaccination Helpful 
8.10.2. Children's experiences of vaccination: Vaccination unhelpful 
8.10.3. Children's experiences of vaccination: Vaccine had side effects 
8.10.4. Children's experiences of vaccination: Negative consequences (effects) of 
vaccination 
8.11. Participant does not vaccinate children 
8.12. Participant has been vaccinated since childhood 
8.13. Participant has not been vaccinated since childhood 
9. X Concerns 
9.1 .Concerns: Vaccines cause HIV (NB: Please make notes so we can tell whether people 
are scared of HIV infection through needles or from the vaccination itself.) 
9.2.Concerns: Vaccines cause other diseases 
9.3.Concerns: Vaccines cause difficulties 
9.4.Concerns about normal vaccines 
9.5.Concerns about potential HIV vaccines 
9.5.1.Concerns about affordability 
9.5.2.Concerns: Psycho-social (e.g. disinhibition, stigmatisation etc) 
9.6. Other concerns 
10 X Barriers to vaccination 
10.1. No Barriers to vaccination 
10.2. Barrier to vaccination: Knowledge/Education 
10.3. Barrier to vaccination: Logistics (e.g. transport, money, time etc..) 
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10.4. Barrier to vaccination: Intrapersonal factors (e.g. laziness) 
10.5. Barrier to vaccination: Concern/Fear of risks/safety 
10.6. Barrier to vaccination: Culture/religion 
10.7. Other barriers to vaccination (e.g. resources, poor community etc) 
11. X Suggested measures to remove barriers 
11.1. Education to increase vaccination 
11.2. Other means to increase vaccination 
12. X Alternatives to vaccination 
12.1. No Alternatives to vaccination 
12.2. Yes, alternatives exist 
12.2.1.Sanitation as alternative 
12.2.2.Religious alternatives 
12.2.3."Cultural" alternatives 
12.2.4.Health alternatives (adequate sleep, exercise, diet, vitamins) 
12.3. Alternatives are complementary to vaccination (i.e. they work together) 
12.4. Alternatives are better 
12.5. Alternatives are worse 
12.6. Uncertain 
8.10. Uncertain 
13 X Possible HIV vaccine 
13.1. Never heard of possible HTV vaccine 
13.2. Have heard of possible HIV vaccine 
13.3. Participant mentions an existing HIV "vaccine". 
13.4. HTV vaccine will be useful for prevention 
13.5. HTV vaccine will be useful treatment 
13.6. HTV Vaccine target - healthy people 
13.7. HTV Vaccine target - HIV infected people 
13.8. HIV Vaccine target - All people, everyone 
13.9. HIV Vaccine target - People at risk 
14 X Participation in HIV vaccine trials 
14.1. Willing to participate in HIV vaccine trials 
14.2. Not willing to participate in HIV vaccine trials 
14.3. Animals should be used in trials instead of people 
14.4. Unsure 
14.5. X Requirements before participating 
14.5.1. Require more information before participating in HIV vaccine trials 
14.5.2. Only participate if no significant risks 
14.5.3. Only participate if family cared for after any consequent problems. 
14.5.4. For financial benefit 
15 X Perceived barriers to HIV vaccination trial participation 
15.1.Trial participation barrier: Significant physical risk 
15.2.Trial participation barrier: Significant psycho-social risk (e.g. stigmatisation, 
disinhibition etc.) 
15.3.Trial participation barrier: Fear of injections 
15.4.Trial participation barrier: Other 
16 X Perceived incentives for trial participation: 
16.1.Trial participation incentive: Altruism (e.g. to help people who are dying) 
16.2.Trial participation incentive: Counselling 
16.3.Trial participation incentive: Material benefits (jobs, houses, cash etc...) 
16.4.Trial participation incentive: Education 
16.5.Trial participation incentive: Other 
17 X Sources of information about vaccination 
17.1.Information source: School/University25 
17.2.Information source: Clinics/hospitals 
17.2.1. From doctors/ nurses at clinics 
17.2.2. From notice boards or posters at clinics 
17.3. Information source: Media 
17.4.Information source: Other 
18 X Preferred sources of information 
18.1. Preferred sources of information: Nurses/Doctors/clinics 
18.2. Preferred sources of information: Anyone who is well-informed 




18.4. Preferred sources of information: Trained community members 
18.5. Preferred sources of information: Informal a friends and neighbours 
19 X Specific Educational needs 
19.1. Educational need: None 
19.2. Educational need: Not sure 
19.3. Educational need: General HIV 
19.4. Educational need: General vaccination info 
19.4.1. How it works (mechanisms) 
19.4.2. What vaccines are 
19.4.3. What vaccines are available 
19.5. Educational need: HIV vaccine info 
20 QUERY CODE: ANYTHING THAT IS NOT CLASSIFIABLE UNDER THIS 
CODING SCHEME 
21 X Friends and family and vaccines 
21.1. Friends and family go get vaccinated (Why? Code under code 5) 
21.2. Friends and family don't go get vaccinated (WHY? Code under code 10) 
22.X Vaccination and human rights: 
22.1. There should not be a law forcing people to get vaccinated 
22.2. There should be a law forcing people to get vaccinated 
22.3. Uncertain, ambivalent as to whether there should be a law forcing people 
22.4. Human rights of the population are important in this case 
22.5. Human rights of the individual are important in this case 
23.1 Would like to know more about vaccination 
24 X Personal incentives for trial participation: 
24.1 Trial participation incentive: Altruism (e.g. to help people who are dying) 
24.2 Trial participation incentive: Counselling 
24.3 Trial participation incentive: Material benefits (jobs, houses, cash etc..) 
24.4 Trial participation incentive: Education 
24.5 Trial participation incentive: other 
25 X HIV Vaccine Mechanism 
25.1 Stimulating the immune system 
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